Detection of immunogenic cell death and its relevance for cancer therapy

Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell death & disease Jg. 11; H. 11; S. 1013 - 13
Hauptverfasser:	Fucikova, Jitka, Kepp, Oliver, Kasikova, Lenka, Petroni, Giulia, Yamazaki, Takahiro, Liu, Peng, Zhao, Liwei, Spisek, Radek, Kroemer, Guido, Galluzzi, Lorenzo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 26.11.2020 Springer Nature B.V Nature Publishing Group
Schlagworte:	631/154 631/250/1932 631/67/1059/2325 Adjuvanticity Antibodies Antigen-presenting cells Antigenicity Antineoplastic drugs Antitumor agents Apoptosis Autophagy Biochemistry Biomedical and Life Sciences Calreticulin Cancer Cancer therapies Cell activation Cell Biology Cell Culture Cell death Chemotherapy Drug Discovery - methods HMGB1 protein Humans Immune response Immunogenic Cell Death - immunology Immunogenicity Immunology Immunotherapy - methods Initiation factor eIF-2 Interferon Life Sciences Neoplasms - therapy Phagocytosis Phosphorylation Radiation therapy Review Review Article Transcription
ISSN:	2041-4889, 2041-4889
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer.
AbstractList	Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer. Abstract Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer. Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer.Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer.
ArticleNumber	1013
Author	Kepp, Oliver Spisek, Radek Fucikova, Jitka Yamazaki, Takahiro Zhao, Liwei Galluzzi, Lorenzo Liu, Peng Petroni, Giulia Kasikova, Lenka Kroemer, Guido
Author_xml	– sequence: 1 givenname: Jitka surname: Fucikova fullname: Fucikova, Jitka organization: Sotio, 2nd Faculty of Medicine and University Hospital Motol, Department of Immunology, Charles University – sequence: 2 givenname: Oliver orcidid: 0000-0002-6081-9558 surname: Kepp fullname: Kepp, Oliver organization: Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy – sequence: 3 givenname: Lenka surname: Kasikova fullname: Kasikova, Lenka organization: Sotio, 2nd Faculty of Medicine and University Hospital Motol, Department of Immunology, Charles University – sequence: 4 givenname: Giulia surname: Petroni fullname: Petroni, Giulia organization: Department of Radiation Oncology, Weill Cornell Medical College – sequence: 5 givenname: Takahiro surname: Yamazaki fullname: Yamazaki, Takahiro organization: Department of Radiation Oncology, Weill Cornell Medical College – sequence: 6 givenname: Peng orcidid: 0000-0002-1682-9222 surname: Liu fullname: Liu, Peng organization: Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy – sequence: 7 givenname: Liwei surname: Zhao fullname: Zhao, Liwei organization: Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy – sequence: 8 givenname: Radek surname: Spisek fullname: Spisek, Radek organization: Sotio, 2nd Faculty of Medicine and University Hospital Motol, Department of Immunology, Charles University – sequence: 9 givenname: Guido surname: Kroemer fullname: Kroemer, Guido email: kroemer@orange.fr organization: Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Department of Women’s and Children’s Health, Karolinska Institute, Karolinska University Hospital – sequence: 10 givenname: Lorenzo surname: Galluzzi fullname: Galluzzi, Lorenzo email: deadoc80@gmail.com organization: Department of Radiation Oncology, Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Caryl and Israel Englander Institute for Precision Medicine, Department of Dermatology, Yale University School of Medicine, Université de Paris
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33243969$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-03094981$$DView record in HAL
BookMark	eNp9Ustu1DAUjVARLaU_wAJFYgOLgJ-xvUGqCmUqjcQG1pZjOzMeJfZgOyP173GatrSzqDe-uj6Pq-vztjrxwduqeg_BFwgw_5oIJFA0AIEGYIRgg15VZwgQ2BDOxcmT-rS6SGkHysEYINq-qU4xRgSLVpxVq-82W51d8HXoazeOkw8b652utR2G2liVt7XypnY51dEO9qC8tnUfYq3nKtZ5a6Pa376rXvdqSPbi_j6v_lz_-H21ata_ft5cXa4b3TKeG0qMhqy3xZ1xSAUjmBrAMSWat4ByJYTRCIKuI6WimhMBAEI9wVAjITp8Xt0suiaondxHN6p4K4Ny8q4R4kaqmJ0erBS04x3GDIquJ6Rn3BhBgRGMa24o10Xr26K1n7rRGm19jmp4Jvr8xbut3ISDZK2AFIoi8HkR2B7RVpdrOfcABoIIDg-wYD_dm8Xwd7Ipy9GlecnK2zAliUhLCWYUkwL9eATdhSn6staCYhhRWD68oD48nf7R_-FzCwAtAB1DStH2jxAI5BwiuYRIlhDJuxBJVEj8iKRdVnNAygbc8DIVL9RUfPzGxv9jv8D6B4pZ120
CitedBy_id	crossref_primary_10_1016_j_bioactmat_2022_09_017 crossref_primary_10_1016_j_tranon_2024_102148 crossref_primary_10_1039_D4SC08495K crossref_primary_10_1039_D5MD00039D crossref_primary_10_1186_s12985_022_01842_x crossref_primary_10_1038_s41598_023_35745_w crossref_primary_10_1038_s42003_024_06271_w crossref_primary_10_1186_s12906_023_04221_3 crossref_primary_10_1016_j_bios_2023_115313 crossref_primary_10_1021_acs_jmedchem_5c00969 crossref_primary_10_1186_s12951_023_01885_4 crossref_primary_10_3390_pharmaceutics13101668 crossref_primary_10_34133_bmr_0086 crossref_primary_10_1002_smtd_202300252 crossref_primary_10_3390_cells11091415 crossref_primary_10_1016_j_ijbiomac_2024_138346 crossref_primary_10_1007_s11426_021_1126_x crossref_primary_10_1016_j_biomaterials_2024_122608 crossref_primary_10_1038_s12276_024_01260_9 crossref_primary_10_1146_annurev_immunol_101721_040259 crossref_primary_10_1002_ange_202406602 crossref_primary_10_1016_j_biomaterials_2023_122446 crossref_primary_10_3390_ijms231810222 crossref_primary_10_3389_fonc_2023_1178681 crossref_primary_10_3389_fgene_2022_1010787 crossref_primary_10_1039_D5CS00088B crossref_primary_10_1016_j_mtbio_2025_102047 crossref_primary_10_3389_fonc_2022_1049888 crossref_primary_10_1017_erm_2024_27 crossref_primary_10_1016_j_bmcl_2025_130114 crossref_primary_10_2147_IJN_S442446 crossref_primary_10_1038_s41423_024_01245_8 crossref_primary_10_1186_s12916_024_03375_2 crossref_primary_10_3390_md21120600 crossref_primary_10_1002_smll_202503117 crossref_primary_10_3389_fimmu_2022_882257 crossref_primary_10_1016_j_phymed_2025_156514 crossref_primary_10_1080_2162402X_2022_2104551 crossref_primary_10_1172_JCI181143 crossref_primary_10_1016_j_ijpharm_2025_125612 crossref_primary_10_1038_s41416_023_02466_w crossref_primary_10_3390_cancers16122189 crossref_primary_10_3390_cancers17142324 crossref_primary_10_1007_s13346_025_01938_1 crossref_primary_10_3390_cells12172147 crossref_primary_10_1016_j_arr_2025_102786 crossref_primary_10_1016_j_biomaterials_2023_122333 crossref_primary_10_3389_fcell_2023_1146195 crossref_primary_10_1002_adhm_202400030 crossref_primary_10_3390_ph18081203 crossref_primary_10_1089_ars_2023_0257 crossref_primary_10_1080_17474086_2023_2208861 crossref_primary_10_1007_s12274_023_6042_y crossref_primary_10_3724_abbs_2025128 crossref_primary_10_1007_s00432_023_04950_5 crossref_primary_10_1159_000536549 crossref_primary_10_1002_ange_202115247 crossref_primary_10_1016_j_bbcan_2023_188946 crossref_primary_10_1016_j_ebiom_2021_103624 crossref_primary_10_3390_ijms232415551 crossref_primary_10_1007_s13659_023_00401_3 crossref_primary_10_1016_j_intimp_2025_115057 crossref_primary_10_1016_j_jconrel_2025_113782 crossref_primary_10_1093_intimm_dxae061 crossref_primary_10_3389_fonc_2023_1147805 crossref_primary_10_1038_s41419_022_05514_0 crossref_primary_10_1080_2162402X_2025_2527303 crossref_primary_10_1136_jitc_2025_012211 crossref_primary_10_1016_j_actbio_2024_04_013 crossref_primary_10_3389_fimmu_2024_1357217 crossref_primary_10_1016_j_tranon_2024_102052 crossref_primary_10_1002_anie_202212866 crossref_primary_10_1016_j_imlet_2024_106942 crossref_primary_10_1080_1061186X_2025_2522868 crossref_primary_10_1186_s12916_022_02614_8 crossref_primary_10_1016_j_ccr_2024_216006 crossref_primary_10_1038_s41573_022_00538_9 crossref_primary_10_1002_adhm_202102584 crossref_primary_10_3390_pathogens12040607 crossref_primary_10_1016_j_tranon_2022_101600 crossref_primary_10_15212_bioi_2024_0012 crossref_primary_10_3389_fonc_2023_1167105 crossref_primary_10_3390_ijms231912018 crossref_primary_10_1021_acs_chemrev_5c00041 crossref_primary_10_1016_j_ijbiomac_2024_138434 crossref_primary_10_1039_D2BM00601D crossref_primary_10_1007_s00210_025_04036_8 crossref_primary_10_2217_imt_2022_0121 crossref_primary_10_1002_smtd_202201401 crossref_primary_10_1016_j_ccell_2022_01_006 crossref_primary_10_1016_j_bbcan_2025_189393 crossref_primary_10_1016_j_phrs_2023_106646 crossref_primary_10_1186_s13045_022_01247_x crossref_primary_10_3389_fimmu_2024_1357101 crossref_primary_10_1016_j_omton_2025_201027 crossref_primary_10_3389_fimmu_2023_1297493 crossref_primary_10_3390_biom12020246 crossref_primary_10_3390_ijms26104525 crossref_primary_10_1016_j_jconrel_2025_113721 crossref_primary_10_1093_jnci_djad118 crossref_primary_10_1016_j_bioactmat_2022_08_016 crossref_primary_10_1002_adfm_202303195 crossref_primary_10_1186_s12890_023_02792_y crossref_primary_10_1016_j_biomaterials_2025_123184 crossref_primary_10_1007_s00281_022_00970_4 crossref_primary_10_1016_j_jconrel_2021_07_038 crossref_primary_10_1021_jacs_5c06120 crossref_primary_10_1134_S0006350924701161 crossref_primary_10_1016_j_jtbi_2025_112231 crossref_primary_10_1002_adhm_202203028 crossref_primary_10_1002_adma_202407525 crossref_primary_10_3389_fimmu_2024_1390263 crossref_primary_10_3390_cancers13225652 crossref_primary_10_1038_s41598_023_33785_w crossref_primary_10_1007_s11426_024_2130_1 crossref_primary_10_1007_s00259_023_06485_w crossref_primary_10_1002_adma_202308977 crossref_primary_10_1016_j_ccr_2025_216846 crossref_primary_10_3892_br_2021_1462 crossref_primary_10_1016_j_biopha_2022_113662 crossref_primary_10_1016_j_ijpharm_2023_123043 crossref_primary_10_1016_j_actbio_2023_02_014 crossref_primary_10_1186_s12645_023_00173_y crossref_primary_10_1002_anie_202406602 crossref_primary_10_1016_j_jcis_2024_07_145 crossref_primary_10_3389_fgene_2024_1419819 crossref_primary_10_1080_1744666X_2024_2372327 crossref_primary_10_1007_s10549_021_06369_3 crossref_primary_10_1038_s41467_022_33831_7 crossref_primary_10_1016_j_biomaterials_2024_122913 crossref_primary_10_1177_11769351251323239 crossref_primary_10_3389_fimmu_2022_980709 crossref_primary_10_1016_j_jconrel_2025_113984 crossref_primary_10_1002_bco2_119 crossref_primary_10_1002_advs_202504155 crossref_primary_10_1016_j_actbio_2022_10_001 crossref_primary_10_1186_s12906_023_03904_1 crossref_primary_10_1002_ajh_26823 crossref_primary_10_1007_s11431_023_2574_0 crossref_primary_10_3389_fphar_2022_1029020 crossref_primary_10_3390_pharmaceutics14081564 crossref_primary_10_1016_j_nano_2023_102681 crossref_primary_10_1155_2023_9020236 crossref_primary_10_3390_cells10051208 crossref_primary_10_1002_adma_202417422 crossref_primary_10_1002_cmdc_202300131 crossref_primary_10_1002_ctd2_160 crossref_primary_10_3390_ijms222313051 crossref_primary_10_1002_adhm_202301517 crossref_primary_10_3390_cancers13246259 crossref_primary_10_1158_0008_5472_CAN_23_2812 crossref_primary_10_1186_s12951_024_02695_y crossref_primary_10_3390_vaccines11050925 crossref_primary_10_1016_j_toxicon_2025_108477 crossref_primary_10_1080_17435889_2025_2500906 crossref_primary_10_1016_j_canlet_2022_215928 crossref_primary_10_1007_s12094_024_03650_x crossref_primary_10_1177_17588359231161409 crossref_primary_10_1002_cnr2_70300 crossref_primary_10_1002_iid3_70214 crossref_primary_10_1038_s41598_025_91401_5 crossref_primary_10_3389_fimmu_2024_1498781 crossref_primary_10_1002_smtd_202201327 crossref_primary_10_1002_adma_202205701 crossref_primary_10_1002_adhm_202301401 crossref_primary_10_3390_vaccines13050476 crossref_primary_10_1016_j_yexcr_2021_112678 crossref_primary_10_1039_D3NR03881E crossref_primary_10_1038_s41420_025_02415_x crossref_primary_10_2147_IJN_S494970 crossref_primary_10_3389_fimmu_2022_956984 crossref_primary_10_1002_cbf_3823 crossref_primary_10_1016_j_biomaterials_2024_122694 crossref_primary_10_1016_j_biopha_2024_116203 crossref_primary_10_1111_1751_7915_70028 crossref_primary_10_3390_pharmaceutics14091908 crossref_primary_10_3390_cancers13071626 crossref_primary_10_1002_adhm_202301693 crossref_primary_10_1007_s00262_021_03013_3 crossref_primary_10_1186_s12951_025_03404_z crossref_primary_10_1002_cac2_70024 crossref_primary_10_1038_s12276_023_01078_x crossref_primary_10_3892_mmr_2025_13515 crossref_primary_10_1016_j_ctrv_2025_102884 crossref_primary_10_3390_cells11233826 crossref_primary_10_1016_j_scib_2023_10_004 crossref_primary_10_1038_s42003_024_06930_y crossref_primary_10_1182_blood_2024024709 crossref_primary_10_1186_s12951_023_01844_z crossref_primary_10_1016_j_jphotobiol_2025_113126 crossref_primary_10_1158_0008_5472_CAN_23_3325 crossref_primary_10_3390_ph14100972 crossref_primary_10_34133_bmr_0232 crossref_primary_10_2147_IJN_S526305 crossref_primary_10_1186_s12951_022_01682_5 crossref_primary_10_1016_j_nantod_2023_101834 crossref_primary_10_1080_17435889_2025_2497747 crossref_primary_10_1038_s41420_025_02662_y crossref_primary_10_1038_s41416_024_02848_8 crossref_primary_10_7717_peerj_18690 crossref_primary_10_3389_fimmu_2022_837293 crossref_primary_10_1016_j_heliyon_2024_e41380 crossref_primary_10_1002_adhm_202300018 crossref_primary_10_1080_2162402X_2022_2086752 crossref_primary_10_1093_jrr_rrad107 crossref_primary_10_1002_anbr_202500088 crossref_primary_10_1016_j_jddst_2024_106349 crossref_primary_10_1002_cac2_12487 crossref_primary_10_3389_fimmu_2021_781466 crossref_primary_10_1186_s12967_023_04450_7 crossref_primary_10_1016_j_freeradbiomed_2025_01_042 crossref_primary_10_1002_smll_202503848 crossref_primary_10_1371_journal_pone_0330906 crossref_primary_10_1186_s40364_024_00628_3 crossref_primary_10_3390_cells12071049 crossref_primary_10_1002_smll_202401299 crossref_primary_10_3390_pharmaceutics14122752 crossref_primary_10_1002_advs_202413387 crossref_primary_10_1016_j_fmre_2022_03_009 crossref_primary_10_1080_1061186X_2024_2445772 crossref_primary_10_1016_j_csbj_2024_04_054 crossref_primary_10_1007_s10120_025_01623_9 crossref_primary_10_1016_j_jcis_2025_138849 crossref_primary_10_1016_j_ccell_2022_10_013 crossref_primary_10_1016_j_ejmech_2024_116534 crossref_primary_10_1002_adhm_202202830 crossref_primary_10_1080_14712598_2021_1936494 crossref_primary_10_3389_fimmu_2022_992855 crossref_primary_10_3389_fcell_2022_962389 crossref_primary_10_1002_advs_202207475 crossref_primary_10_1016_j_ejmech_2022_114830 crossref_primary_10_1002_cmdc_202400537 crossref_primary_10_1016_j_actbio_2022_06_033 crossref_primary_10_3390_biomedicines12061184 crossref_primary_10_1002_tox_23793 crossref_primary_10_1016_j_lfs_2023_122396 crossref_primary_10_1158_1078_0432_CCR_21_4332 crossref_primary_10_1016_j_apsb_2025_05_021 crossref_primary_10_1002_smll_202500104 crossref_primary_10_1021_acsami_5c11256 crossref_primary_10_1007_s00432_023_05017_1 crossref_primary_10_1039_D4BM00241E crossref_primary_10_1016_j_biomaterials_2021_121076 crossref_primary_10_1007_s12672_021_00439_0 crossref_primary_10_1080_08830185_2024_2333275 crossref_primary_10_1080_21645515_2024_2427464 crossref_primary_10_1002_smll_202404211 crossref_primary_10_1080_2162402X_2021_1973197 crossref_primary_10_1016_j_bioactmat_2022_08_028 crossref_primary_10_1021_acs_jmedchem_5c00699 crossref_primary_10_1038_s41418_023_01245_7 crossref_primary_10_1016_j_freeradbiomed_2023_03_009 crossref_primary_10_1038_s41568_021_00346_0 crossref_primary_10_1016_j_heliyon_2023_e14820 crossref_primary_10_2147_IJN_S457782 crossref_primary_10_1002_adfm_202302825 crossref_primary_10_3390_pharmaceutics16081064 crossref_primary_10_1016_j_cclet_2025_111013 crossref_primary_10_3389_fimmu_2022_968686 crossref_primary_10_1007_s12672_025_02793_9 crossref_primary_10_1016_j_bioactmat_2024_01_026 crossref_primary_10_1007_s11033_025_10370_0 crossref_primary_10_1080_10715762_2023_2193308 crossref_primary_10_2147_JIR_S410140 crossref_primary_10_3390_biom13030421 crossref_primary_10_1111_cas_15525 crossref_primary_10_1007_s10142_023_01238_2 crossref_primary_10_1016_j_intimp_2025_114982 crossref_primary_10_1186_s12935_022_02585_z crossref_primary_10_1002_tox_24338 crossref_primary_10_1039_D5BM00914F crossref_primary_10_1186_s12885_023_11647_y crossref_primary_10_7759_cureus_74834 crossref_primary_10_3390_cancers14235952 crossref_primary_10_1016_j_cej_2024_153656 crossref_primary_10_1111_imr_13237 crossref_primary_10_1021_jacs_4c11636 crossref_primary_10_3389_fimmu_2021_713158 crossref_primary_10_3389_fonc_2023_1047973 crossref_primary_10_3389_fchem_2024_1378233 crossref_primary_10_3390_md21040225 crossref_primary_10_1016_j_jconrel_2021_11_011 crossref_primary_10_1016_j_immuni_2024_04_025 crossref_primary_10_1002_adma_202417735 crossref_primary_10_1016_j_jcis_2024_04_151 crossref_primary_10_1016_j_cej_2025_164958 crossref_primary_10_3390_biomedicines13010203 crossref_primary_10_1016_j_cclet_2021_10_074 crossref_primary_10_3389_fimmu_2024_1425602 crossref_primary_10_1016_j_snr_2025_100316 crossref_primary_10_1002_adhm_202302597 crossref_primary_10_3390_cancers15123089 crossref_primary_10_1007_s12602_024_10330_3 crossref_primary_10_1016_j_nantod_2023_101995 crossref_primary_10_1002_adma_202311733 crossref_primary_10_1002_anie_202404822 crossref_primary_10_1016_j_critrevonc_2025_104658 crossref_primary_10_3389_fimmu_2022_828386 crossref_primary_10_1002_ange_202212866 crossref_primary_10_3390_biom13030528 crossref_primary_10_1038_s41467_024_49156_6 crossref_primary_10_1007_s40843_024_3170_1 crossref_primary_10_1245_s10434_022_13025_7 crossref_primary_10_1038_s41598_024_63852_9 crossref_primary_10_1016_j_biomaterials_2024_122751 crossref_primary_10_1016_j_eurpolymj_2024_113333 crossref_primary_10_3389_fimmu_2022_760763 crossref_primary_10_1007_s12672_025_02278_9 crossref_primary_10_1016_j_cej_2023_141369 crossref_primary_10_1097_SHK_0000000000002641 crossref_primary_10_3390_cancers14010141 crossref_primary_10_1038_s41571_024_00859_1 crossref_primary_10_3389_fimmu_2024_1375767 crossref_primary_10_1038_s41388_025_03488_9 crossref_primary_10_1016_j_cej_2025_161652 crossref_primary_10_1002_smll_202300244 crossref_primary_10_1007_s44178_024_00113_9 crossref_primary_10_1016_j_biomaterials_2023_122442 crossref_primary_10_1002_ange_202116669 crossref_primary_10_1016_j_ccr_2024_216284 crossref_primary_10_1088_1361_6463_ad2832 crossref_primary_10_1007_s10495_025_02176_z crossref_primary_10_1016_j_canlet_2023_216239 crossref_primary_10_1186_s12645_025_00341_2 crossref_primary_10_1073_pnas_2500489122 crossref_primary_10_1088_2043_6262_ad002a crossref_primary_10_1016_j_bioorg_2024_107930 crossref_primary_10_1007_s11684_023_1048_0 crossref_primary_10_1016_j_cclet_2025_111214 crossref_primary_10_2217_nnm_2023_0332 crossref_primary_10_1016_j_drup_2023_100963 crossref_primary_10_1016_j_cej_2025_162041 crossref_primary_10_1039_D2NR02620A crossref_primary_10_1371_journal_pone_0307024 crossref_primary_10_1182_bloodadvances_2022009444 crossref_primary_10_1186_s13046_021_02065_8 crossref_primary_10_1016_j_nantod_2025_102644 crossref_primary_10_1016_j_cej_2024_155593 crossref_primary_10_1016_j_phymed_2023_154682 crossref_primary_10_3389_fimmu_2025_1572034 crossref_primary_10_1016_j_heliyon_2024_e27103 crossref_primary_10_1016_j_ijpharm_2024_123810 crossref_primary_10_3390_cancers14081926 crossref_primary_10_1186_s12951_025_03471_2 crossref_primary_10_1016_j_bcp_2023_115612 crossref_primary_10_1002_advs_202102678 crossref_primary_10_1080_2162402X_2022_2158610 crossref_primary_10_1111_php_13865 crossref_primary_10_3892_ijo_2024_5639 crossref_primary_10_1080_14737140_2024_2320187 crossref_primary_10_1016_j_intimp_2025_115406 crossref_primary_10_1016_j_carbpol_2023_121643 crossref_primary_10_1126_sciadv_adv6990 crossref_primary_10_1007_s00277_023_05292_5 crossref_primary_10_1007_s00262_022_03216_2 crossref_primary_10_1097_JCMA_0000000000001209 crossref_primary_10_3389_frtra_2025_1575703 crossref_primary_10_1515_nanoph_2021_0304 crossref_primary_10_3389_fonc_2021_731598 crossref_primary_10_1002_smll_202300280 crossref_primary_10_1021_acs_nanolett_5c01290 crossref_primary_10_1080_21645515_2024_2437918 crossref_primary_10_1016_j_intimp_2024_113031 crossref_primary_10_1039_D2BM01126C crossref_primary_10_1016_j_jconrel_2025_114081 crossref_primary_10_1038_s41467_023_40826_5 crossref_primary_10_1093_bjd_ljaf102 crossref_primary_10_1021_acsnano_5c06418 crossref_primary_10_1177_10732748241299074 crossref_primary_10_3389_fimmu_2022_1059331 crossref_primary_10_1093_mtomcs_mfae032 crossref_primary_10_1016_j_actbio_2024_09_037 crossref_primary_10_1158_1535_7163_MCT_24_1015 crossref_primary_10_3389_fimmu_2024_1287824 crossref_primary_10_3390_cancers17091584 crossref_primary_10_1111_imr_13251 crossref_primary_10_1002_adfm_202214824 crossref_primary_10_1016_j_nantod_2023_102070 crossref_primary_10_1038_s43018_023_00571_6 crossref_primary_10_1016_j_jconrel_2025_02_059 crossref_primary_10_1016_j_matdes_2022_110656 crossref_primary_10_3390_cells11223655 crossref_primary_10_3389_fimmu_2022_993771 crossref_primary_10_1002_advs_202504886 crossref_primary_10_3390_vaccines11111701 crossref_primary_10_1002_adma_202205462 crossref_primary_10_1016_j_ijpharm_2024_123844 crossref_primary_10_1016_j_canlet_2023_216435 crossref_primary_10_1002_adhm_202304436 crossref_primary_10_26599_NR_2025_94907675 crossref_primary_10_1016_j_retram_2023_103380 crossref_primary_10_3389_fimmu_2022_851169 crossref_primary_10_1016_j_biomaterials_2022_121409 crossref_primary_10_3390_nu17172809 crossref_primary_10_1002_smtd_202201086 crossref_primary_10_1186_s40364_024_00599_5 crossref_primary_10_1002_mabi_202300093 crossref_primary_10_1016_j_apsb_2025_07_017 crossref_primary_10_1016_j_cej_2023_142085 crossref_primary_10_1002_adhm_202500785 crossref_primary_10_1016_j_heliyon_2023_e19799 crossref_primary_10_1016_j_nantod_2024_102286 crossref_primary_10_1038_s41541_024_01055_z crossref_primary_10_1136_jitc_2021_003155 crossref_primary_10_3390_cells11223705 crossref_primary_10_3389_fimmu_2024_1479483 crossref_primary_10_1038_s41598_024_52353_4 crossref_primary_10_1186_s12951_025_03583_9 crossref_primary_10_1038_s41598_022_10700_3 crossref_primary_10_22465_juo_255000300015 crossref_primary_10_1002_cam4_71065 crossref_primary_10_1007_s10495_023_01879_5 crossref_primary_10_1016_j_cej_2025_163576 crossref_primary_10_1038_s41423_023_00990_6 crossref_primary_10_1016_j_omton_2024_200845 crossref_primary_10_1002_advs_202308248 crossref_primary_10_1016_j_intimp_2022_109661 crossref_primary_10_1007_s12011_024_04376_1 crossref_primary_10_3389_fimmu_2021_705361 crossref_primary_10_1002_advs_202403520 crossref_primary_10_1080_2162402X_2023_2218782 crossref_primary_10_1002_cnr2_2073 crossref_primary_10_1002_cac2_12590 crossref_primary_10_1016_j_nantod_2024_102179 crossref_primary_10_1021_jacs_5c00255 crossref_primary_10_1080_21645515_2025_2505349 crossref_primary_10_3389_fgene_2022_1035484 crossref_primary_10_3390_cancers17030496 crossref_primary_10_1016_j_cclet_2025_111038 crossref_primary_10_1016_j_jconrel_2024_07_028 crossref_primary_10_1016_j_jcis_2025_138715 crossref_primary_10_1002_adfm_202425286 crossref_primary_10_1158_0008_5472_CAN_22_3382 crossref_primary_10_1002_ange_202402949 crossref_primary_10_1016_j_jconrel_2024_07_020 crossref_primary_10_1038_s41467_025_58266_8 crossref_primary_10_1136_jitc_2022_006602 crossref_primary_10_1186_s12967_023_04017_6 crossref_primary_10_3389_fphar_2022_1093666 crossref_primary_10_1016_j_biopha_2023_115251 crossref_primary_10_1016_j_jconrel_2024_10_043 crossref_primary_10_1038_s41467_025_63269_6 crossref_primary_10_1186_s12951_023_02031_w crossref_primary_10_1002_adfm_202510798 crossref_primary_10_3389_fcimb_2022_910466 crossref_primary_10_1016_j_pdpdt_2022_102879 crossref_primary_10_3389_fgene_2021_764245 crossref_primary_10_1007_s13167_023_00327_3 crossref_primary_10_3389_fmed_2022_1102550 crossref_primary_10_1002_adtp_202300209 crossref_primary_10_2174_0113892029319505240821063238 crossref_primary_10_1021_jacs_2c02435 crossref_primary_10_1016_j_compbiomed_2025_110646 crossref_primary_10_3389_fphar_2025_1651165 crossref_primary_10_1002_smtd_202401501 crossref_primary_10_1186_s12943_023_01833_8 crossref_primary_10_3390_biology10090856 crossref_primary_10_3390_cancers14225665 crossref_primary_10_1002_smll_202301041 crossref_primary_10_1007_s00535_024_02120_z crossref_primary_10_2147_IJN_S413204 crossref_primary_10_1016_j_nantod_2025_102699 crossref_primary_10_1002_cac2_12579 crossref_primary_10_1016_j_ijpharm_2023_122655 crossref_primary_10_1016_j_jconrel_2022_10_007 crossref_primary_10_1097_MNM_0000000000001941 crossref_primary_10_3390_ijms24087057 crossref_primary_10_1016_j_ejpb_2024_114510 crossref_primary_10_1021_acscentsci_5c00509 crossref_primary_10_3390_cancers14163935 crossref_primary_10_1038_s41598_025_85774_w crossref_primary_10_1016_j_oraloncology_2023_106520 crossref_primary_10_1016_j_jconrel_2023_12_023 crossref_primary_10_1136_jitc_2025_011717 crossref_primary_10_1007_s44178_024_00143_3 crossref_primary_10_1002_anie_202402949 crossref_primary_10_1186_s12920_024_02042_y crossref_primary_10_2147_IJN_S419712 crossref_primary_10_1038_s41598_024_72697_1 crossref_primary_10_1093_pnasnexus_pgad484 crossref_primary_10_1016_j_bbamem_2025_184429 crossref_primary_10_1016_j_clbc_2021_03_007 crossref_primary_10_1016_j_jcis_2025_138193 crossref_primary_10_1158_1078_0432_CCR_24_1594 crossref_primary_10_1038_s41420_025_02360_9 crossref_primary_10_1007_s10528_024_10697_6 crossref_primary_10_1186_s12943_023_01761_7 crossref_primary_10_3892_ol_2023_14061 crossref_primary_10_1002_ejic_202500146 crossref_primary_10_1002_smtd_202201457 crossref_primary_10_1016_j_biopha_2023_115627 crossref_primary_10_3389_fimmu_2023_1138920 crossref_primary_10_1002_advs_202305217 crossref_primary_10_1016_j_intimp_2021_107733 crossref_primary_10_1016_j_biopha_2023_115509 crossref_primary_10_1002_ange_202404822 crossref_primary_10_1002_adhm_202202017 crossref_primary_10_1016_j_ctrv_2022_102361 crossref_primary_10_3390_cells10040930 crossref_primary_10_1038_s41551_024_01259_7 crossref_primary_10_3389_ftox_2022_887228 crossref_primary_10_1016_j_jconrel_2024_07_074 crossref_primary_10_1038_s41467_024_52104_z crossref_primary_10_3389_fonc_2025_1581951 crossref_primary_10_1002_adhm_202400784 crossref_primary_10_1021_acsabm_5c00498 crossref_primary_10_3390_pharmaceutics15102430 crossref_primary_10_1002_smll_202202462 crossref_primary_10_1093_jimmun_vkaf125 crossref_primary_10_1016_j_bioactmat_2024_04_023 crossref_primary_10_1016_j_biomaterials_2023_122064 crossref_primary_10_1016_j_diagmicrobio_2024_116401 crossref_primary_10_1186_s12880_024_01492_1 crossref_primary_10_3390_ph14111068 crossref_primary_10_3390_cancers16172958 crossref_primary_10_1002_smll_202304014 crossref_primary_10_1186_s12885_023_10992_2 crossref_primary_10_3389_fimmu_2022_1038226 crossref_primary_10_3389_fimmu_2025_1621812 crossref_primary_10_3390_cancers15123204 crossref_primary_10_1111_odi_14077 crossref_primary_10_3389_fonc_2024_1495321 crossref_primary_10_3389_fimmu_2023_1145481 crossref_primary_10_3389_fonc_2021_635007 crossref_primary_10_1002_advs_202507864 crossref_primary_10_3389_fped_2022_999684 crossref_primary_10_1016_j_jinorgbio_2021_111628 crossref_primary_10_3390_ijms23116312 crossref_primary_10_1186_s13014_025_02711_x crossref_primary_10_1016_j_ctarc_2023_100713 crossref_primary_10_1016_j_ijpharm_2025_125901 crossref_primary_10_3390_pharmaceutics14102234 crossref_primary_10_1093_bioadv_vbac092 crossref_primary_10_1016_j_ejphar_2024_176913 crossref_primary_10_3390_ijms26136440 crossref_primary_10_3390_cancers15225350 crossref_primary_10_1016_j_actbio_2024_07_027 crossref_primary_10_1002_smll_202306303 crossref_primary_10_4049_jimmunol_2100963 crossref_primary_10_1002_adma_202301352 crossref_primary_10_3389_frtra_2025_1571516 crossref_primary_10_1016_j_ccr_2025_216808 crossref_primary_10_3389_fimmu_2023_1169541 crossref_primary_10_1038_s41598_023_43440_z crossref_primary_10_1136_jitc_2022_006235 crossref_primary_10_1002_anie_202115247 crossref_primary_10_1021_acs_nanolett_5c00358 crossref_primary_10_1007_s11010_023_04873_2 crossref_primary_10_3892_ijo_2025_5755 crossref_primary_10_1002_cbic_202200621 crossref_primary_10_1002_adhm_202304284 crossref_primary_10_1016_j_heliyon_2024_e27630 crossref_primary_10_1016_j_jconrel_2024_06_001 crossref_primary_10_1016_j_nantod_2023_102109 crossref_primary_10_1186_s12985_025_02672_3 crossref_primary_10_1016_j_canlet_2024_217155 crossref_primary_10_1016_j_mtbio_2025_101463 crossref_primary_10_1021_acsnano_5c02569 crossref_primary_10_1021_jacs_4c15644 crossref_primary_10_1177_10781552251324896 crossref_primary_10_1016_j_neo_2022_100796 crossref_primary_10_3390_ijms26125849 crossref_primary_10_1016_j_bbcan_2021_188585 crossref_primary_10_1016_j_mattod_2025_03_018 crossref_primary_10_3389_fimmu_2022_1021935 crossref_primary_10_1515_nanoph_2021_0171 crossref_primary_10_3390_ijms24076446 crossref_primary_10_1111_1754_9485_13399 crossref_primary_10_3389_fimmu_2022_998653 crossref_primary_10_3389_fimmu_2025_1579420 crossref_primary_10_1039_D2SC03756D crossref_primary_10_1007_s12032_022_01659_2 crossref_primary_10_1002_adfm_202409736 crossref_primary_10_3390_cancers13215335 crossref_primary_10_1039_D4BM00665H crossref_primary_10_3389_fimmu_2023_1294434 crossref_primary_10_1080_2162402X_2021_1952539 crossref_primary_10_1186_s12951_025_03311_3 crossref_primary_10_3390_cancers13030433 crossref_primary_10_3390_ijms24065303 crossref_primary_10_3389_fimmu_2023_1087978 crossref_primary_10_1007_s10238_024_01533_7 crossref_primary_10_3390_cells11223672 crossref_primary_10_1158_2326_6066_CIR_23_0729 crossref_primary_10_1016_j_jconrel_2023_05_044 crossref_primary_10_3389_fimmu_2023_1073561 crossref_primary_10_1016_j_biomaterials_2025_123592 crossref_primary_10_1186_s12890_023_02410_x crossref_primary_10_3390_biomedicines10092142 crossref_primary_10_1007_s11684_025_1134_6 crossref_primary_10_1016_j_nantod_2024_102335 crossref_primary_10_1186_s40164_022_00371_1 crossref_primary_10_1016_j_nantod_2024_102213 crossref_primary_10_1039_D3BM00770G crossref_primary_10_1080_2162402X_2023_2219591 crossref_primary_10_3389_fcell_2024_1363121 crossref_primary_10_3390_pharmaceutics14081630 crossref_primary_10_3390_ph16101367 crossref_primary_10_3390_ijms221910672 crossref_primary_10_1002_adma_202504404 crossref_primary_10_3390_ijms26073373 crossref_primary_10_1021_acsmedchemlett_5c00238 crossref_primary_10_3390_ijms23169327 crossref_primary_10_1038_s41435_021_00161_5 crossref_primary_10_1111_php_13951 crossref_primary_10_1016_j_freeradbiomed_2024_01_005 crossref_primary_10_1016_j_cej_2025_164487 crossref_primary_10_1002_adhm_202202360 crossref_primary_10_3390_ijms25042222 crossref_primary_10_1016_j_intimp_2024_111854 crossref_primary_10_3389_fimmu_2022_994034 crossref_primary_10_3390_v13071271 crossref_primary_10_1016_j_actbio_2023_10_002 crossref_primary_10_1158_0008_5472_CAN_24_0693 crossref_primary_10_1002_anie_202116669 crossref_primary_10_1016_j_ijpharm_2024_124968 crossref_primary_10_1002_adma_202410998 crossref_primary_10_1007_s00262_024_03924_x crossref_primary_10_1038_s41565_024_01784_1 crossref_primary_10_1002_smsc_202300314 crossref_primary_10_1007_s00432_023_05370_1 crossref_primary_10_1016_j_heliyon_2022_e10775 crossref_primary_10_3389_fphar_2025_1584245 crossref_primary_10_1016_j_bbrc_2024_149976 crossref_primary_10_1016_j_tips_2023_05_006 crossref_primary_10_3390_cancers15051468 crossref_primary_10_3390_biology12060808 crossref_primary_10_1007_s40265_023_01907_3 crossref_primary_10_3389_fimmu_2022_884827 crossref_primary_10_1016_j_intimp_2022_109166 crossref_primary_10_2147_DDDT_S461594 crossref_primary_10_3389_fonc_2021_743540 crossref_primary_10_1016_j_actbio_2023_04_027 crossref_primary_10_1002_smll_202304032 crossref_primary_10_1016_j_bioactmat_2024_06_038 crossref_primary_10_3389_fpubh_2021_666282 crossref_primary_10_1002_smll_202203659 crossref_primary_10_1016_j_ctarc_2021_100427 crossref_primary_10_1038_s41419_023_06408_5 crossref_primary_10_1007_s11060_023_04491_4 crossref_primary_10_1016_j_bioadv_2024_213996 crossref_primary_10_1016_j_canlet_2024_217079 crossref_primary_10_3390_cells10112936 crossref_primary_10_1002_advs_202205803 crossref_primary_10_3390_pharmaceutics14091762 crossref_primary_10_1186_s12951_024_02297_8 crossref_primary_10_3390_biomedicines11082245 crossref_primary_10_1016_j_ejmech_2025_118122 crossref_primary_10_2147_OTT_S521346 crossref_primary_10_3390_jpm12111840 crossref_primary_10_1016_j_ymthe_2021_09_015 crossref_primary_10_1016_j_matdes_2023_112378 crossref_primary_10_1016_j_ymthe_2024_05_014 crossref_primary_10_1016_j_phymed_2024_155828 crossref_primary_10_3389_fimmu_2022_1017400 crossref_primary_10_3390_cancers13112566 crossref_primary_10_3390_cancers16234075 crossref_primary_10_3390_cells14110823
Cites_doi	10.1016/S1097-2765(00)80136-7 10.3389/fimmu.2015.00402 10.1038/s41577-019-0215-7 10.4049/jimmunol.1003477 10.1177/0961203312468964 10.1038/s41467-020-15726-7 10.1016/S0092-8674(03)00758-X 10.1182/blood-2016-08-731737 10.1056/NEJMoa1709937 10.1038/nature15520 10.1016/bs.ircmb.2018.08.001 10.1038/bjc.2017.376 10.1038/s41573-018-0011-2 10.1016/bs.ircmb.2019.10.001 10.1038/s41467-018-03555-8 10.1038/s41590-019-0561-4 10.1038/nature04515 10.1016/j.cytogfr.2013.01.005 10.1186/s40425-019-0781-z 10.1016/bs.mie.2019.05.001 10.1016/bs.ircmb.2019.07.008 10.1038/nrmicro3390 10.3389/fcell.2019.00050 10.1091/mbc.e12-05-0385 10.1038/s41573-018-0007-y 10.1038/s41591-019-0432-4 10.1038/s41586-020-2229-5 10.1038/nri1961 10.1016/bs.ircmb.2019.06.001 10.1016/S0065-2776(06)90001-7 10.1038/emboj.2009.1 10.1080/2162402X.2019.1641391 10.1016/bs.ircmb.2019.06.002 10.1158/0008-5472.CAN-15-1142 10.1038/s41568-019-0210-0 10.1038/s41568-020-0246-1 10.1038/s41467-017-01062-w 10.1126/science.1203486 10.1152/physrev.00043.2006 10.1016/bs.ircmb.2018.07.002 10.1111/jnc.14874 10.1080/2162402X.2019.1655964 10.1038/gt.2011.205 10.1007/s00134-020-05941-7 10.1080/2162402X.2019.1667743 10.1038/s41580-020-0232-1 10.1038/s41577-019-0218-4 10.1126/science.aaa4971 10.1038/s41577-018-0117-0 10.1172/JCI123319 10.1080/2162402X.2018.1431089 10.1038/nrd.2018.210 10.1007/s00262-012-1268-7 10.1080/2162402X.2019.1710398 10.1038/s41467-019-09415-3 10.4161/onci.27878 10.1007/s00240-016-0902-9 10.1038/ncomms4554 10.1097/CJI.0b013e31804efc76 10.2337/dc10-1219 10.1038/ncomms15618 10.1073/pnas.1512832112 10.1186/1471-2164-10-365 10.1038/nri3787 10.1080/2162402X.2018.1526250 10.1016/bs.ircmb.2019.07.003 10.1016/bs.mie.2019.10.006 10.1016/bs.ircmb.2018.08.004 10.1016/S0076-6879(00)05499-9 10.1016/0003-2697(75)90723-X 10.1016/bs.ircmb.2019.07.006 10.3389/fimmu.2017.01383 10.1080/2162402X.2018.1471440 10.1016/j.cell.2016.03.014 10.1038/s41576-019-0151-1 10.1080/2162402X.2019.1591875 10.1038/16729 10.1038/nri.2017.9 10.1038/nrd3976 10.1038/s41577-018-0029-z 10.1016/j.tcb.2018.08.005 10.4049/jimmunol.1300057 10.1038/nrc3380 10.1038/nri.2017.131 10.1152/ajpcell.00401.2005 10.1186/1479-5876-9-139 10.1371/journal.ppat.1006326 10.1016/bs.ircmb.2019.08.002 10.1158/0008-5472.CAN-12-0420 10.1038/nri.2017.21 10.1038/nm.2028 10.1038/s41571-020-0413-z 10.15252/emmm.201911622 10.1016/bs.ircmb.2018.05.010 10.1080/2162402X.2018.1446720 10.1038/s41571-018-0046-7 10.1016/bs.ircmb.2019.07.005 10.1038/s41571-020-0382-2 10.1126/science.aad0779 10.1038/nri3607 10.1016/bs.ircmb.2019.10.002 10.1016/j.molcel.2017.06.017 10.1038/s41591-018-0232-2 10.1158/2159-8290.CD-19-0541 10.1016/bs.mie.2019.05.050 10.1038/nrc.2018.6 10.1038/nrc.2016.71 10.1080/2162402X.2017.1404216 10.1038/s41568-019-0162-4 10.1038/s41573-019-0043-2 10.1016/bs.ircmb.2016.09.003 10.1038/nature08296 10.1186/s40425-018-0464-1 10.2119/molmed.2015.00087 10.1126/science.aat5314 10.1080/2162402X.2019.1606665 10.1038/s41419-019-1819-3 10.1016/S1470-2045(19)30171-8 10.1080/2162402X.2020.1721810 10.1016/bs.ircmb.2019.10.003 10.1158/1078-0432.CCR-09-0155 10.1038/414916a 10.1038/cdd.2009.44 10.1016/j.jneuroim.2020.577266 10.1007/978-1-4939-9717-6_15 10.1038/emboj.2011.497 10.1080/2162402X.2020.1744947 10.1038/cddis.2016.47 10.1038/nrm3270 10.1038/nri.2016.116 10.1038/s41577-018-0014-6 10.1016/B978-0-12-397926-1.00007-X 10.1172/JCI76344 10.1007/s10495-019-01532-0 10.1038/s41571-020-0387-x 10.1126/scitranslmed.3003807 10.1016/bs.ircmb.2018.08.006 10.1016/j.imlet.2015.02.007 10.4049/jimmunol.1402706 10.1016/j.tcb.2019.01.003 10.1016/j.expneurol.2019.113072 10.1038/s41418-017-0044-9 10.1038/s41590-020-0708-3 10.1021/cb800025k 10.1038/cdd.2013.75 10.1371/journal.ppat.1006985 10.1038/nm1622 10.1038/s41573-019-0032-5 10.1007/s12192-011-0306-2 10.1038/s41580-020-0244-x 10.1038/35012626 10.1016/bs.ircmb.2018.08.005 10.1093/nar/gkw1005 10.4161/onci.25771 10.1038/s41590-020-0751-0 10.1038/s41577-019-0210-z 10.1038/nm.3708 10.1038/srep19507 10.1111/jcmm.14356 10.1002/mc.23050 10.1016/bs.mie.2017.01.004 10.1038/nm.4078 10.1158/2159-8290.CD-18-1218 10.1136/jitc-2019-000337 10.1080/2162402X.2015.1008866 10.1038/s41568-019-0144-6 10.1016/bs.ircmb.2018.07.003 10.1016/j.cell.2005.08.032 10.1038/s41598-020-64865-w 10.3389/fimmu.2018.00496 10.1136/annrheumdis-2018-213197 10.1038/cddis.2013.156 10.1371/journal.pbio.3000355 10.1016/j.immuni.2013.07.008 10.1080/2162402X.2018.1523097 10.1016/j.ccell.2018.05.013 10.1016/j.virol.2008.04.033 10.1038/s41556-018-0042-2 10.1038/nmeth.1928 10.1016/j.immuni.2004.07.017 10.1038/s41580-019-0133-3 10.1038/nri3713 10.1080/2162402X.2019.1638212 10.1158/0008-5472.CAN-12-0851 10.1038/s41577-019-0165-0 10.3324/haematol.2019.223933 10.1002/ijc.28766 10.1016/j.immuni.2014.10.019 10.1080/2162402X.2019.1570779 10.1016/bs.ircmb.2019.07.004 10.1073/pnas.1921799117 10.1038/nrd3203 10.1038/s41568-018-0037-0 10.1074/jbc.M704300200 10.1038/nrc3171 10.1080/2162402X.2018.1466765 10.1158/2326-6066.CIR-18-0403 10.4161/onci.27297 10.1158/2326-6066.CIR-17-0581 10.1038/s41568-019-0183-z 10.1126/science.1208347 10.1002/0471143030.cb1519s57 10.1038/s41375-020-0788-y
ContentType	Journal Article
Copyright	The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml	– notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 1XC VOOES 5PM DOA
DOI	10.1038/s41419-020-03221-2
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE CrossRef Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2041-4889
EndPage	13
ExternalDocumentID	oai_doaj_org_article_95b8b33719bf44f78dd950d978c8d58c PMC7691519 oai:HAL:hal-03094981v1 33243969 10_1038_s41419_020_03221_2
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: Weill Cornell Medical College – fundername: Centre de Recherche des Cordelliers – fundername: Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from the Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), by a Rapid Response Grant from the Functional Genomics Initiative (New York, US), by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US), and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US) and Sotio a.s. (Prague, Czech Republic). – fundername: Sotio – fundername: Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). – fundername: INSERM – fundername: ;
GroupedDBID	--- 0R~ 3V. 53G 5VS 70F 7X7 88A 88I 8FE 8FH 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO E3Z EBLON EBS EMOBN FRP FYUFA GNUQQ GROUPED_DOAJ HCIFZ HMCUK HYE HZ~ KQ8 LK8 M0L M2P M48 M7P M~E NAO O5R O5S O9- OK1 PIMPY PQQKQ PROAC RNT RPM SNYQT TR2 UKHRP W2D AASML AAYXX AFFHD CITATION PHGZM PHGZT PQGLB CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 PUEGO 1XC ADRAZ CAG COF EJD IPNFZ RIG VOOES 5PM
ID	FETCH-LOGICAL-c678t-54dc17fe396781597435d08354c86058a99dc210bb499d5c8490022f431c299b3
IEDL.DBID	BENPR
ISICitedReferencesCount	791
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000595956300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2041-4889
IngestDate	Fri Oct 03 12:43:59 EDT 2025 Tue Nov 04 01:54:13 EST 2025 Tue Oct 14 20:40:53 EDT 2025 Thu Sep 04 17:30:26 EDT 2025 Tue Oct 07 07:03:43 EDT 2025 Thu Jan 02 22:56:00 EST 2025 Tue Nov 18 21:08:04 EST 2025 Sat Nov 29 05:57:15 EST 2025 Fri Feb 21 02:36:54 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Language	English
License	Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c678t-54dc17fe396781597435d08354c86058a99dc210bb499d5c8490022f431c299b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 PMCID: PMC7691519
ORCID	0000-0002-6081-9558 0000-0002-1682-9222 0000-0002-9334-4405 0000-0003-2257-8500
OpenAccessLink	https://www.proquest.com/docview/2473251221?pq-origsite=%requestingapplication%
PMID	33243969
PQID	2473251221
PQPubID	2041963
PageCount	13
ParticipantIDs	doaj_primary_oai_doaj_org_article_95b8b33719bf44f78dd950d978c8d58c pubmedcentral_primary_oai_pubmedcentral_nih_gov_7691519 hal_primary_oai_HAL_hal_03094981v1 proquest_miscellaneous_2465437534 proquest_journals_2473251221 pubmed_primary_33243969 crossref_primary_10_1038_s41419_020_03221_2 crossref_citationtrail_10_1038_s41419_020_03221_2 springer_journals_10_1038_s41419_020_03221_2
PublicationCentury	2000
PublicationDate	2020-11-26
PublicationDateYYYYMMDD	2020-11-26
PublicationDate_xml	– month: 11 year: 2020 text: 2020-11-26 day: 26
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Cell death & disease
PublicationTitleAbbrev	Cell Death Dis
PublicationTitleAlternate	Cell Death Dis
PublicationYear	2020
Publisher	Nature Publishing Group UK Springer Nature B.V Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Springer Nature B.V – name: Nature Publishing Group
References	Oh (CR134) 2019; 7 Sarkar (CR193) 2018; 77 Ren (CR20) 2020; 9 Kepp (CR206) 2019; 8 Bommareddy, Zloza, Rabkin, Kaufman (CR162) 2019; 8 Ngwa (CR53) 2018; 18 Stagg (CR123) 2012; 72 Feng (CR210) 2019; 19 Kasikova (CR91) 2019; 7 Vessey, Ho, Jobling, Wang, Fletcher (CR182) 2020; 2041 Bergmann (CR110) 2011; 9 Demaria (CR196) 2015; 112 Deutsch, Chargari, Galluzzi, Kroemer (CR47) 2019; 20 Patel, Leone, Horton, Powell (CR177) 2019; 18 Schcolnik-Cabrera (CR93) 2019; 24 Khodarev (CR128) 2019; 344 CR170 Antonia (CR56) 2017; 377 Allard, Allard, Buisseret, Stagg (CR124) 2020; 17 Garrido (CR73) 2011; 187 Dong Xda (CR159) 2007; 30 Byrne (CR97) 2013; 190 Rodriguez-Ruiz (CR127) 2019; 8 Clifford (CR202) 2002; 8 Schreiber, Old, Smyth (CR2) 2011; 331 Dunn, Koebel, Schreiber (CR10) 2006; 6 Liu, Beyer, Aebersold (CR191) 2016; 165 West, Shadel (CR44) 2017; 17 Smyth, Dunn, Schreiber (CR1) 2006; 90 Gardai (CR95) 2005; 123 Burnstock (CR117) 2007; 87 Forveille (CR181) 2019; 629 Clifford (CR201) 2000; 9 Muller (CR137) 2017; 8 Tittarelli (CR111) 2012; 61 Zhu (CR198) 2015; 194 Pozzi (CR74) 2016; 22 Reineke, Dougherty, Pierre, Lloyd (CR158) 2012; 23 Li (CR176) 2019; 9 Cooke (CR203) 2019; 151 McLaughlin (CR131) 2020; 20 Sistigu (CR126) 2014; 20 Yamamoto (CR23) 2020; 581 Brown, Sundar, Lopez (CR55) 2018; 118 Pol (CR50) 2015; 4 Elliott (CR118) 2009; 461 Hetz, Papa (CR148) 2018; 69 Hetz, Chevet, Harding (CR153) 2013; 12 Swanson, Deng, Ting (CR121) 2019; 19 Chalmin, Humblin, Ghiringhelli, Vegran (CR8) 2018; 341 Marceau, Roy, Bouthillier (CR180) 2014; 534 Hetz (CR151) 2012; 13 Salmon, Remark, Gnjatic, Merad (CR4) 2019; 19 van Schadewijk, van’t Wout, Stolk, Hiemstra (CR155) 2012; 17 Serrano-Del Valle, Anel, Naval, Marzo (CR70) 2019; 7 Wang (CR165) 2017; 45 Skopelja-Gardner (CR195) 2020; 10 Dunn, Old, Schreiber (CR12) 2004; 21 Pacheco, Merianda, Twiss, Gallo (CR144) 2020; 323 Harding, Zhang, Ron (CR154) 1999; 397 Lei, Geng, Zhong (CR163) 2020; 345 Donnelly (CR67) 2013; 20 Yamazaki, Buqué, Ames, Galluzzi (CR58) 2020; 9 Ye (CR48) 2020; 9 Wu (CR197) 2016; 6 Downey (CR192) 2017; 13 Bezu (CR209) 2015; 6 Tang (CR63) 2018; 17 Giglio (CR71) 2018; 7 Liu (CR59) 2019; 10 Hoang, Udupa, Le (CR179) 2019; 347 Worbs, Hammerschmidt, Forster (CR29) 2017; 17 Peng (CR9) 2015; 527 Yang, Wang, Chavan, Andersson (CR100) 2015; 21 Haen, Loffler, Rammensee, Brossart (CR15) 2020; 17 Paludan, Reinert, Hornung (CR42) 2019; 19 Mariathasan (CR120) 2006; 440 Boada-Romero, Martinez, Heckmann, Green (CR41) 2020; 21 Follo, Cheng, Richards, Bueno, Broaddus (CR116) 2019; 58 Guermonprez, Gerber-Ferder, Vaivode, Bourdely, Helft (CR92) 2019; 349 Ohta, Sitkovsky (CR122) 2001; 414 Martins (CR114) 2014; 21 Gangaplara (CR138) 2018; 14 Sautes-Fridman, Petitprez, Calderaro, Fridman (CR5) 2019; 19 Cherney, Scholey, Sochett, Bradley, Reich (CR186) 2011; 34 Smith (CR105) 2018; 7 Hayashi (CR156) 2007; 282 Ghiringhelli (CR119) 2009; 15 Hopfner, Hornung (CR130) 2020; 21 Krysko, Løve Aaes, Bachert, Vandenabeele, Krysko (CR31) 2013; 4 Michaud (CR86) 2011; 334 Vacchelli (CR125) 2015; 350 Moore (CR188) 2018; 7 Truxova (CR98) 2020; 105 Coudert, Adjibade, Mazroui (CR205) 2014; 87 Mohajertehran, Ayatollahi, Khazaeni, Shakeri, Mohtasham (CR168) 2018; 30 Kawasaki, Kawai (CR133) 2019; 344 Galluzzi, Spranger, Fuchs, López-Soto (CR3) 2019; 29 Sprooten, Agostinis, Garg (CR32) 2019; 348 Kotsias, Cebrian, Alloatti (CR22) 2019; 348 Huang (CR72) 2018; 7 Branchini, Southworth (CR172) 2017; 589 Yamazaki (CR89) 2020; 21 Zhu (CR101) 2015; 125 Krombach (CR81) 2019; 8 Vigneron (CR108) 2019; 8 Becker-Merok, Ostli-Eilersten, Lester, Nossent (CR185) 2013; 22 Gao, Zhu, Liu, Nabi (CR145) 2019; 17 Zhou (CR39) 2019; 23 Vacchelli (CR28) 2013; 2 Candolfi (CR161) 2009; 15 Rodriguez-Ruiz, Vitale, Harrington, Melero, Galluzzi (CR77) 2020; 21 Vacchelli (CR61) 2014; 3 Chabanon (CR75) 2019; 129 Vanpouille-Box, Hoffmann, Galluzzi (CR43) 2019; 18 Costa-Mattioli, Walter (CR147) 2020; 368 Fucikova (CR80) 2014; 135 Xiao (CR49) 2018; 7 Leylek, Idoyaga (CR187) 2019; 349 Park (CR102) 2006; 290 Han, Vesely (CR62) 2019; 342 Formenti (CR184) 2018; 24 Lee, Radford (CR26) 2019; 348 Voorwerk (CR57) 2019; 25 D’Amico (CR60) 2019; 7 Gry (CR190) 2009; 10 Boncompain (CR169) 2012; 9 Glimcher, Lee, Iwakoshi (CR150) 2020; 21 Prischi, Nowak, Carrara, Ali (CR157) 2014; 5 Sun (CR66) 2015; 164 Tatsuno (CR79) 2019; 10 Poon, Lucas, Rossi, Ravichandran (CR90) 2014; 14 Han, Hanlon, Sobolev, Chaudhury, Edelson (CR207) 2019; 349 Garg (CR78) 2012; 31 Galluzzi, Humeau, Buque, Zitvogel, Kroemer (CR46) 2020; 17 Ivashkiv (CR13) 2018; 18 Lundin, Thore (CR173) 1975; 66 Truxova (CR54) 2017; 330 Aranda (CR64) 2014; 3 Dudek, Garg, Krysko, De Ruysscher, Agostinis (CR69) 2013; 24 Taguchi (CR104) 2000; 405 Altman, Stine, Dang (CR178) 2016; 16 Gong, Liu, Jiang, Zhou (CR34) 2020; 20 Fucikova (CR45) 2015; 6 Krysko (CR38) 2012; 12 Gay, Symmons, Gangloff, Bryant (CR107) 2014; 14 Roumenina, Daugan, Petitprez, Sautes-Fridman, Fridman (CR7) 2019; 19 Martinek, Wu, Cadena, Banchereau, Palucka (CR27) 2019; 348 Galon, Angell, Bedognetti, Marincola (CR6) 2013; 39 Takeda (CR136) 2018; 9 Apetoh (CR103) 2007; 13 Rosenzweig, Nillegoda, Mayer, Bukau (CR84) 2019; 20 Bordignon (CR199) 2008; 377 Gardai (CR96) 2003; 115 Rao, Gharib, Han (CR11) 2019; 342 Chassé, Boulben, Costache, Cormier, Morales (CR204) 2017; 45 Rybstein, Bravo-San Pedro, Kroemer, Galluzzi (CR88) 2018; 20 Bezu (CR149) 2018; 25 Suren (CR167) 2018; 23 Sprooten (CR112) 2019; 8 Diamond (CR189) 2018; 6 Yatim, Cullen, Albert (CR37) 2017; 17 Balan, Saxena, Bhardwaj (CR33) 2019; 348 Pantelidou (CR76) 2019; 9 Bruck (CR164) 2020; 46 Galon, Bruni (CR52) 2019; 18 Los (CR142) 2008; 3 Vitale (CR18) 2019; 29 Hu, Ott, Wu (CR19) 2018; 18 Nayagom (CR109) 2019; 8 Lundin (CR174) 2000; 305 Schumacher, Schreiber (CR14) 2015; 348 Galluzzi (CR16) 2020; 8 Humeau (CR85) 2020; 12 Anderson, Macleod (CR115) 2019; 347 Takahashi (CR194) 2018; 9 Borrie, Maleki Vareki (CR65) 2018; 341 Zhou (CR200) 2016; 7 Medler (CR129) 2019; 344 Fucikova (CR99) 2016; 128 Fucikova (CR146) 2016; 76 Bommareddy, Shettigar, Kaufman (CR68) 2018; 18 Bloes, Kretschmer, Peschel (CR35) 2015; 13 Dubyak (CR171) 2019; 629 Hwang, Pike, Royce, Mahal, Loeffler (CR51) 2018; 15 Hennessy, Parker, O’Neill (CR212) 2010; 9 Vanpouille-Box (CR139) 2017; 8 McNab, Mayer-Barber, Sher, Wack, O’Garra (CR36) 2015; 15 Rainbolt, Frydman (CR152) 2020; 117 Zhao, Liu, Kepp, Kroemer (CR160) 2019; 629 Deng (CR140) 2014; 41 Garg (CR40) 2010; 1805 Galluzzi (CR113) 2009; 16 Smith (CR17) 2019; 19 CR175 Wculek (CR208) 2020; 20 Lee (CR25) 2020; 11 Sade-Feldman (CR21) 2017; 8 Suzuki (CR166) 2012; 72 Borden (CR183) 2019; 18 Medzhitov (CR106) 1998; 2 Kalbasi, Ribas (CR24) 2020; 20 Amon (CR30) 2019; 349 Panaretakis (CR94) 2009; 28 Los, Wood (CR141) 2007; 356 Bek (CR135) 2019; 8 Bezu (CR87) 2018; 7 Vanpouille-Box, Demaria, Formenti, Galluzzi (CR83) 2018; 34 Chao, Majeti, Weissman (CR211) 2011; 12 Di Virgilio, Sarti, Falzoni, De Marchi, Adinolfi (CR82) 2018; 18 Motwani, Pesiridis, Fitzgerald (CR132) 2019; 20 Menger (CR143) 2012; 4 C Hetz (3221_CR151) 2012; 13 SC Formenti (3221_CR184) 2018; 24 JH Lee (3221_CR25) 2020; 11 Y Suzuki (3221_CR166) 2012; 72 J Fucikova (3221_CR146) 2016; 76 ME Rodriguez-Ruiz (3221_CR127) 2019; 8 YS Lee (3221_CR26) 2019; 348 C Lei (3221_CR163) 2020; 345 ME Rodriguez-Ruiz (3221_CR77) 2020; 21 T Medler (3221_CR129) 2019; 344 J Humeau (3221_CR85) 2020; 12 L Zhao (3221_CR160) 2019; 629 F Di Virgilio (3221_CR82) 2018; 18 SJ Antonia (3221_CR56) 2017; 377 O Krysko (3221_CR31) 2013; 4 A Lundin (3221_CR173) 1975; 66 W Ye (3221_CR48) 2020; 9 BR Branchini (3221_CR172) 2017; 589 SP Haen (3221_CR15) 2020; 17 Y Liu (3221_CR191) 2016; 165 E Vacchelli (3221_CR61) 2014; 3 CM Anderson (3221_CR115) 2019; 347 R Rosenzweig (3221_CR84) 2019; 20 C Pozzi (3221_CR74) 2016; 22 I Vitale (3221_CR18) 2019; 29 E Vacchelli (3221_CR28) 2013; 2 TK Rainbolt (3221_CR152) 2020; 117 D Peng (3221_CR9) 2015; 527 KP Hopfner (3221_CR130) 2020; 21 CH Patel (3221_CR177) 2019; 18 H Salmon (3221_CR4) 2019; 19 N Yatim (3221_CR37) 2017; 17 TN Schumacher (3221_CR14) 2015; 348 E Boada-Romero (3221_CR41) 2020; 21 I Truxova (3221_CR98) 2020; 105 LB Ivashkiv (3221_CR13) 2018; 18 J Martinek (3221_CR27) 2019; 348 T Panaretakis (3221_CR94) 2009; 28 G Garrido (3221_CR73) 2011; 187 F Mohajertehran (3221_CR168) 2018; 30 A Serrano-Del Valle (3221_CR70) 2019; 7 A Taguchi (3221_CR104) 2000; 405 LH Glimcher (3221_CR150) 2020; 21 MJ Smyth (3221_CR1) 2006; 90 M Sade-Feldman (3221_CR21) 2017; 8 EC Moore (3221_CR188) 2018; 7 S Bek (3221_CR135) 2019; 8 JS Brown (3221_CR55) 2018; 118 LT Roumenina (3221_CR7) 2019; 19 P Han (3221_CR207) 2019; 349 E Vacchelli (3221_CR125) 2015; 350 RD Schreiber (3221_CR2) 2011; 331 L Amon (3221_CR30) 2019; 349 J Fucikova (3221_CR80) 2014; 135 L Bezu (3221_CR87) 2018; 7 H Chassé (3221_CR204) 2017; 45 SK Cooke (3221_CR203) 2019; 151 L Kasikova (3221_CR91) 2019; 7 T Yamazaki (3221_CR58) 2020; 9 HP Harding (3221_CR154) 1999; 397 BJ Altman (3221_CR178) 2016; 16 3221_CR175 3221_CR170 M Gry (3221_CR190) 2009; 10 S Forveille (3221_CR181) 2019; 629 M Michaud (3221_CR86) 2011; 334 PK Bommareddy (3221_CR162) 2019; 8 J Sprooten (3221_CR32) 2019; 348 G Gao (3221_CR145) 2019; 17 GP Dunn (3221_CR10) 2006; 6 L Deng (3221_CR140) 2014; 41 S Skopelja-Gardner (3221_CR195) 2020; 10 P Liu (3221_CR59) 2019; 10 L Bezu (3221_CR149) 2018; 25 MP Chao (3221_CR211) 2011; 12 RM Chabanon (3221_CR75) 2019; 129 PK Bommareddy (3221_CR68) 2018; 18 C Vanpouille-Box (3221_CR43) 2019; 18 J Fucikova (3221_CR45) 2015; 6 I Martins (3221_CR114) 2014; 21 A Schcolnik-Cabrera (3221_CR93) 2019; 24 AD Garg (3221_CR40) 2010; 1805 X Han (3221_CR62) 2019; 342 D Suren (3221_CR167) 2018; 23 M Candolfi (3221_CR161) 2009; 15 DV Krysko (3221_CR38) 2012; 12 P Giglio (3221_CR71) 2018; 7 A Ohta (3221_CR122) 2001; 414 F Marceau (3221_CR180) 2014; 534 W Ngwa (3221_CR53) 2018; 18 AM Dudek (3221_CR69) 2013; 24 A Kalbasi (3221_CR24) 2020; 20 J Sprooten (3221_CR112) 2019; 8 L Menger (3221_CR143) 2012; 4 L Galluzzi (3221_CR16) 2020; 8 JH Oh (3221_CR134) 2019; 7 J Galon (3221_CR52) 2019; 18 G Hoang (3221_CR179) 2019; 347 R Xiao (3221_CR49) 2018; 7 CC Smith (3221_CR17) 2019; 19 SR Paludan (3221_CR42) 2019; 19 GV Los (3221_CR141) 2007; 356 H Yang (3221_CR100) 2015; 21 J Bordignon (3221_CR199) 2008; 377 XY Li (3221_CR176) 2019; 9 X Zhu (3221_CR101) 2015; 125 JM Diamond (3221_CR189) 2018; 6 AD Garg (3221_CR78) 2012; 31 JC Byrne (3221_CR97) 2013; 190 MD Rybstein (3221_CR88) 2018; 20 C Follo (3221_CR116) 2019; 58 C Vigneron (3221_CR108) 2019; 8 A Gangaplara (3221_CR138) 2018; 14 SJ Gardai (3221_CR95) 2005; 123 E Deutsch (3221_CR47) 2019; 20 A Hayashi (3221_CR156) 2007; 282 L Voorwerk (3221_CR57) 2019; 25 B Nayagom (3221_CR109) 2019; 8 KV Swanson (3221_CR121) 2019; 19 EC Borden (3221_CR183) 2019; 18 J Tang (3221_CR63) 2018; 17 A Becker-Merok (3221_CR185) 2013; 22 C Hetz (3221_CR153) 2013; 12 A Sistigu (3221_CR126) 2014; 20 F Chalmin (3221_CR8) 2018; 341 GR Dubyak (3221_CR171) 2019; 629 C Bergmann (3221_CR110) 2011; 9 R Leylek (3221_CR187) 2019; 349 SK Wculek (3221_CR208) 2020; 20 E Bruck (3221_CR164) 2020; 46 KA Vessey (3221_CR182) 2020; 2041 O Kepp (3221_CR206) 2019; 8 I Truxova (3221_CR54) 2017; 330 S Mariathasan (3221_CR120) 2006; 440 E Dong Xda (3221_CR159) 2007; 30 T Gong (3221_CR34) 2020; 20 DA Bloes (3221_CR35) 2015; 13 NN Khodarev (3221_CR128) 2019; 344 A van Schadewijk (3221_CR155) 2012; 17 C Pantelidou (3221_CR76) 2019; 9 T Kawasaki (3221_CR133) 2019; 344 J Stagg (3221_CR123) 2012; 72 B Allard (3221_CR124) 2020; 17 J Fucikova (3221_CR99) 2016; 128 NJ Gay (3221_CR107) 2014; 14 SJ Gardai (3221_CR96) 2003; 115 FY Huang (3221_CR72) 2018; 7 C Vanpouille-Box (3221_CR139) 2017; 8 T Yamazaki (3221_CR89) 2020; 21 H Wu (3221_CR197) 2016; 6 M McLaughlin (3221_CR131) 2020; 20 J Galon (3221_CR6) 2013; 39 G Burnstock (3221_CR117) 2007; 87 J Krombach (3221_CR81) 2019; 8 A Lundin (3221_CR174) 2000; 305 OG Donnelly (3221_CR67) 2013; 20 GP Dunn (3221_CR12) 2004; 21 AP West (3221_CR44) 2017; 17 EJ Hennessy (3221_CR212) 2010; 9 M Costa-Mattioli (3221_CR147) 2020; 368 H Zhou (3221_CR200) 2016; 7 J Downey (3221_CR192) 2017; 13 M Feng (3221_CR210) 2019; 19 L Galluzzi (3221_CR46) 2020; 17 A Takahashi (3221_CR194) 2018; 9 IK Poon (3221_CR90) 2014; 14 F McNab (3221_CR36) 2015; 15 R Medzhitov (3221_CR106) 1998; 2 T Worbs (3221_CR29) 2017; 17 J Pol (3221_CR50) 2015; 4 F Aranda (3221_CR64) 2014; 3 P Guermonprez (3221_CR92) 2019; 349 K Yamamoto (3221_CR23) 2020; 581 S Balan (3221_CR33) 2019; 348 AE Borrie (3221_CR65) 2018; 341 L Bezu (3221_CR209) 2015; 6 L Galluzzi (3221_CR113) 2009; 16 GV Los (3221_CR142) 2008; 3 W Zhu (3221_CR198) 2015; 194 Z Hu (3221_CR19) 2018; 18 O Demaria (3221_CR196) 2015; 112 WL Hwang (3221_CR51) 2018; 15 Y Wang (3221_CR165) 2017; 45 E Muller (3221_CR137) 2017; 8 A Pacheco (3221_CR144) 2020; 323 C Hetz (3221_CR148) 2018; 69 G Boncompain (3221_CR169) 2012; 9 JS Park (3221_CR102) 2006; 290 M Smith (3221_CR105) 2018; 7 M Motwani (3221_CR132) 2019; 20 S Rao (3221_CR11) 2019; 342 C Sun (3221_CR66) 2015; 164 F Kotsias (3221_CR22) 2019; 348 L Coudert (3221_CR205) 2014; 87 C Sautes-Fridman (3221_CR5) 2019; 19 L Apetoh (3221_CR103) 2007; 13 F Ghiringhelli (3221_CR119) 2009; 15 F Prischi (3221_CR157) 2014; 5 MR Elliott (3221_CR118) 2009; 461 Y Ren (3221_CR20) 2020; 9 LC Reineke (3221_CR158) 2012; 23 J Zhou (3221_CR39) 2019; 23 JL Clifford (3221_CR201) 2000; 9 JL Clifford (3221_CR202) 2002; 8 Y Takeda (3221_CR136) 2018; 9 K Tatsuno (3221_CR79) 2019; 10 L Galluzzi (3221_CR3) 2019; 29 A Tittarelli (3221_CR111) 2012; 61 MK Sarkar (3221_CR193) 2018; 77 DZ Cherney (3221_CR186) 2011; 34 C Vanpouille-Box (3221_CR83) 2018; 34 L D’Amico (3221_CR60) 2019; 7
References_xml	– volume: 2 start-page: 253 year: 1998 end-page: 258 ident: CR106 article-title: MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways publication-title: Mol. Cell doi: 10.1016/S1097-2765(00)80136-7 – volume: 6 start-page: 402 year: 2015 ident: CR45 article-title: Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00402 – volume: 20 start-page: 95 year: 2020 end-page: 112 ident: CR34 article-title: DAMP-sensing receptors in sterile inflammation and inflammatory diseases publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0215-7 – volume: 187 start-page: 4954 year: 2011 end-page: 4966 ident: CR73 article-title: Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody publication-title: J. Immunol. doi: 10.4049/jimmunol.1003477 – volume: 22 start-page: 155 year: 2013 end-page: 163 ident: CR185 article-title: Circulating interferon-alpha2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation publication-title: Lupus doi: 10.1177/0961203312468964 – volume: 11 year: 2020 ident: CR25 article-title: Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition publication-title: Nat. Commun. doi: 10.1038/s41467-020-15726-7 – volume: 115 start-page: 13 year: 2003 end-page: 23 ident: CR96 article-title: By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation publication-title: Cell doi: 10.1016/S0092-8674(03)00758-X – volume: 128 start-page: 3113 year: 2016 end-page: 3124 ident: CR99 article-title: Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients publication-title: Blood doi: 10.1182/blood-2016-08-731737 – volume: 377 start-page: 1919 year: 2017 end-page: 1929 ident: CR56 article-title: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709937 – volume: 527 start-page: 249 year: 2015 end-page: 253 ident: CR9 article-title: Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy publication-title: Nature doi: 10.1038/nature15520 – volume: 342 start-page: 149 year: 2019 end-page: 173 ident: CR11 article-title: Cancer immunosurveillance by T cells publication-title: Int Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.001 – volume: 118 start-page: 312 year: 2018 end-page: 324 ident: CR55 article-title: Combining DNA damaging therapeutics with immunotherapy: more haste, less speed publication-title: Br. J. Cancer doi: 10.1038/bjc.2017.376 – volume: 18 start-page: 219 year: 2019 end-page: 234 ident: CR183 article-title: Interferons alpha and beta in cancer: therapeutic opportunities from new insights publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0011-2 – volume: 349 start-page: 55 year: 2019 end-page: 151 ident: CR30 article-title: Transcriptional control of dendritic cell development and functions publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.10.001 – volume: 9 year: 2018 ident: CR194 article-title: Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells publication-title: Nat. Commun. doi: 10.1038/s41467-018-03555-8 – volume: 19 start-page: 215 year: 2019 end-page: 227 ident: CR4 article-title: Host tissue determinants of tumour immunity publication-title: Nat. Rev. Cancer – volume: 21 start-page: 120 year: 2020 end-page: 134 ident: CR77 article-title: Immunological impact of cell death signaling driven by radiation on the tumor microenvironment publication-title: Nat. Immunol. doi: 10.1038/s41590-019-0561-4 – volume: 440 start-page: 228 year: 2006 end-page: 232 ident: CR120 article-title: Cryopyrin activates the inflammasome in response to toxins and ATP publication-title: Nature doi: 10.1038/nature04515 – volume: 24 start-page: 319 year: 2013 end-page: 333 ident: CR69 article-title: Inducers of immunogenic cancer cell death publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2013.01.005 – volume: 7 start-page: 312 year: 2019 ident: CR91 article-title: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0781-z – volume: 629 start-page: 177 year: 2019 end-page: 193 ident: CR160 article-title: Methods for measuring HMGB1 release during immunogenic cell death publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2019.05.001 – volume: 348 start-page: 179 year: 2019 end-page: 215 ident: CR27 article-title: Interplay between dendritic cells and cancer cells publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.008 – volume: 13 start-page: 95 year: 2015 end-page: 104 ident: CR35 article-title: Enemy attraction: bacterial agonists for leukocyte chemotaxis receptors publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro3390 – volume: 7 start-page: 50 year: 2019 ident: CR70 article-title: Immunogenic cell death and immunotherapy of multiple myeloma publication-title: Front. Cell Dev. Biol. doi: 10.3389/fcell.2019.00050 – volume: 23 start-page: 3499 year: 2012 end-page: 3510 ident: CR158 article-title: Large G3BP-induced granules trigger eIF2α phosphorylation publication-title: Mol. Biol. Cell doi: 10.1091/mbc.e12-05-0385 – volume: 18 start-page: 197 year: 2019 end-page: 218 ident: CR52 article-title: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0007-y – volume: 25 start-page: 920 year: 2019 end-page: 928 ident: CR57 article-title: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial publication-title: Nat. Med. doi: 10.1038/s41591-019-0432-4 – volume: 581 start-page: 100 year: 2020 end-page: 105 ident: CR23 article-title: Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I publication-title: Nature doi: 10.1038/s41586-020-2229-5 – volume: 6 start-page: 836 year: 2006 end-page: 848 ident: CR10 article-title: Interferons, immunity and cancer immunoediting publication-title: Nat. Rev. Immunol. doi: 10.1038/nri1961 – volume: 348 start-page: 217 year: 2019 end-page: 262 ident: CR32 article-title: Type I interferons and dendritic cells in cancer immunotherapy publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.06.001 – volume: 90 start-page: 1 year: 2006 end-page: 50 ident: CR1 article-title: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity publication-title: Adv. Immunol. doi: 10.1016/S0065-2776(06)90001-7 – volume: 28 start-page: 578 year: 2009 end-page: 590 ident: CR94 article-title: Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death publication-title: EMBO J. doi: 10.1038/emboj.2009.1 – volume: 8 year: 2019 ident: CR108 article-title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced natural killer cell activity publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1641391 – volume: 347 start-page: 145 year: 2019 end-page: 190 ident: CR115 article-title: Autophagy and cancer cell metabolism publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.06.002 – volume: 76 start-page: 1746 year: 2016 end-page: 1756 ident: CR146 article-title: Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-1142 – volume: 19 start-page: 698 year: 2019 end-page: 715 ident: CR7 article-title: Context-dependent roles of complement in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0210-0 – volume: 20 start-page: 203 year: 2020 end-page: 217 ident: CR131 article-title: Inflammatory microenvironment remodelling by tumour cells after radiotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-020-0246-1 – volume: 8 year: 2017 ident: CR21 article-title: Resistance to checkpoint blockade therapy through inactivation of antigen presentation publication-title: Nat. Commun. doi: 10.1038/s41467-017-01062-w – volume: 331 start-page: 1565 year: 2011 end-page: 1570 ident: CR2 article-title: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion publication-title: Science doi: 10.1126/science.1203486 – volume: 87 start-page: 659 year: 2007 end-page: 797 ident: CR117 article-title: Physiology and pathophysiology of purinergic neurotransmission publication-title: Physiol. Rev. doi: 10.1152/physrev.00043.2006 – volume: 341 start-page: 1 year: 2018 end-page: 61 ident: CR8 article-title: Transcriptional programs underlying Cd4 T cell differentiation and functions publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.07.002 – volume: 87 start-page: 51164 year: 2014 ident: CR205 article-title: Analysis of translation initiation during stress conditions by polysome profiling publication-title: J. Vis. Exp. – volume: 151 start-page: 764 year: 2019 end-page: 776 ident: CR203 article-title: Effects of the presence and absence of amino acids on translation, signaling, and long-term depression in hippocampal slices from Fmr1 knockout mice publication-title: J. Neurochem. doi: 10.1111/jnc.14874 – volume: 8 year: 2019 ident: CR127 article-title: Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1655964 – volume: 20 start-page: 7 year: 2013 end-page: 15 ident: CR67 article-title: Measles virus causes immunogenic cell death in human melanoma publication-title: Gene Ther. doi: 10.1038/gt.2011.205 – volume: 46 start-page: 811 year: 2020 end-page: 812 ident: CR164 article-title: Prolonged elevation of plasma HMGB1 is associated with cognitive impairment in intensive care unit survivors publication-title: Intensive Care Med. doi: 10.1007/s00134-020-05941-7 – volume: 8 year: 2019 ident: CR109 article-title: Immunogenic cell death in a combined synergic gene- and immune-therapy against cancer publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1667743 – volume: 21 start-page: 398 year: 2020 end-page: 414 ident: CR41 article-title: The clearance of dead cells by efferocytosis publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-020-0232-1 – volume: 20 start-page: 25 year: 2020 end-page: 39 ident: CR24 article-title: Tumour-intrinsic resistance to immune checkpoint blockade publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0218-4 – volume: 348 start-page: 69 year: 2015 end-page: 74 ident: CR14 article-title: Neoantigens in cancer immunotherapy publication-title: Science doi: 10.1126/science.aaa4971 – volume: 19 start-page: 141 year: 2019 end-page: 153 ident: CR42 article-title: DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0117-0 – volume: 129 start-page: 1211 year: 2019 end-page: 1228 ident: CR75 article-title: PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer publication-title: J. Clin. Invest. doi: 10.1172/JCI123319 – volume: 7 year: 2018 ident: CR87 article-title: eIF2α phosphorylation: a hallmark of immunogenic cell death publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1431089 – volume: 17 start-page: 854 year: 2018 end-page: 855 ident: CR63 article-title: Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.210 – volume: 61 start-page: 2067 year: 2012 end-page: 2077 ident: CR111 article-title: Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-012-1268-7 – volume: 9 start-page: 1710398 year: 2020 ident: CR48 article-title: ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1710398 – volume: 10 year: 2019 ident: CR59 article-title: Crizotinib-induced immunogenic cell death in non-small cell lung cancer publication-title: Nat. Commun. doi: 10.1038/s41467-019-09415-3 – volume: 3 year: 2014 ident: CR61 article-title: Trial Watch: chemotherapy with immunogenic cell death inducers publication-title: Oncoimmunology doi: 10.4161/onci.27878 – volume: 45 start-page: 159 year: 2017 end-page: 175 ident: CR165 article-title: Urinary MCP-1HMGB1 increased in calcium nephrolithiasis patients and the influence of hypercalciuria on the production of the two cytokines publication-title: Urolithiasis doi: 10.1007/s00240-016-0902-9 – volume: 5 year: 2014 ident: CR157 article-title: Phosphoregulation of Ire1 RNase splicing activity publication-title: Nat. Commun. doi: 10.1038/ncomms4554 – volume: 30 start-page: 596 year: 2007 end-page: 606 ident: CR159 article-title: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy publication-title: J. Immunother. doi: 10.1097/CJI.0b013e31804efc76 – volume: 34 start-page: 177 year: 2011 end-page: 180 ident: CR186 article-title: The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study publication-title: Diabetes Care doi: 10.2337/dc10-1219 – volume: 8 year: 2017 ident: CR139 article-title: DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity publication-title: Nat. Commun. doi: 10.1038/ncomms15618 – volume: 112 start-page: 15408 year: 2015 end-page: 15413 ident: CR196 article-title: STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1512832112 – volume: 10 year: 2009 ident: CR190 article-title: Correlations between RNA and protein expression profiles in 23 human cell lines publication-title: BMC Genomics doi: 10.1186/1471-2164-10-365 – volume: 15 start-page: 87 year: 2015 end-page: 103 ident: CR36 article-title: Type I interferons in infectious disease publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3787 – volume: 7 year: 2018 ident: CR105 article-title: Trial Watch: Toll-like receptor agonists in cancer immunotherapy publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1526250 – volume: 347 start-page: 191 year: 2019 end-page: 223 ident: CR179 article-title: Application of metabolomics technologies toward cancer prognosis and therapy publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.003 – volume: 629 start-page: 81 year: 2019 end-page: 102 ident: CR171 article-title: Luciferase-assisted detection of extracellular ATP and ATP metabolites during immunogenic death of cancer cells publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2019.10.006 – volume: 344 start-page: 1 year: 2019 end-page: 30 ident: CR133 article-title: Discrimination between self and non-self-nucleic acids by the innate immune system publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.004 – volume: 1805 start-page: 53 year: 2010 end-page: 71 ident: CR40 article-title: Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation publication-title: Biochim. Biophys. Acta – volume: 305 start-page: 346 year: 2000 end-page: 370 ident: CR174 article-title: Use of firefly luciferase in ATP-related assays of biomass, enzymes, and metabolites publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(00)05499-9 – volume: 66 start-page: 47 year: 1975 end-page: 63 ident: CR173 article-title: Analytical information obtainable by evaluation of the time course of firefly bioluminescence in the assay of ATP publication-title: Anal. Biochem. doi: 10.1016/0003-2697(75)90723-X – volume: 30 start-page: 261 year: 2018 end-page: 271 ident: CR168 article-title: Overexpression of high-mobility motor box 1 in the blood and tissues of patients with head and neck squamous cell carcinoma publication-title: Iran. J. Otorhinolaryngol. – volume: 348 start-page: 123 year: 2019 end-page: 178 ident: CR26 article-title: The role of dendritic cells in cancer publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.006 – volume: 8 start-page: 1383 year: 2017 ident: CR137 article-title: Toll-like receptor ligands and interferon-gamma synergize for induction of antitumor M1 macrophages publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.01383 – volume: 7 year: 2018 ident: CR49 article-title: Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1471440 – volume: 165 start-page: 535 year: 2016 end-page: 550 ident: CR191 article-title: On the dependency of cellular protein levels on mRNA abundance publication-title: Cell doi: 10.1016/j.cell.2016.03.014 – volume: 20 start-page: 657 year: 2019 end-page: 674 ident: CR132 article-title: DNA sensing by the cGAS-STING pathway in health and disease publication-title: Nat. Rev. Genet. doi: 10.1038/s41576-019-0151-1 – volume: 8 start-page: 1591875 year: 2019 ident: CR162 article-title: Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1591875 – volume: 397 start-page: 271 year: 1999 end-page: 274 ident: CR154 article-title: Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase publication-title: Nature doi: 10.1038/16729 – volume: 17 start-page: 262 year: 2017 end-page: 275 ident: CR37 article-title: Dying cells actively regulate adaptive immune responses publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.9 – volume: 12 start-page: 703 year: 2013 end-page: 719 ident: CR153 article-title: Targeting the unfolded protein response in disease publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3976 – volume: 18 start-page: 545 year: 2018 end-page: 558 ident: CR13 article-title: IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0029-z – volume: 29 start-page: 44 year: 2019 end-page: 65 ident: CR3 article-title: WNT signaling in cancer immunosurveillance publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2018.08.005 – volume: 190 start-page: 5207 year: 2013 end-page: 5215 ident: CR97 article-title: Bruton’s tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin publication-title: J. Immunol. doi: 10.4049/jimmunol.1300057 – volume: 12 start-page: 860 year: 2012 end-page: 875 ident: CR38 article-title: Immunogenic cell death and DAMPs in cancer therapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3380 – volume: 18 start-page: 168 year: 2018 end-page: 182 ident: CR19 article-title: Towards personalized, tumour-specific, therapeutic vaccines for cancer publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.131 – volume: 290 start-page: C917 year: 2006 end-page: C924 ident: CR102 article-title: High mobility group box 1 protein interacts with multiple Toll-like receptors publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00401.2005 – volume: 23 start-page: 1882 year: 2018 end-page: 1886 ident: CR167 article-title: HMGB1 expression in urothelial carcinoma of the bladder publication-title: J. BUON – volume: 9 year: 2011 ident: CR110 article-title: Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas publication-title: J. Transl. Med. doi: 10.1186/1479-5876-9-139 – volume: 13 year: 2017 ident: CR192 article-title: RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to influenza A virus infection publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006326 – volume: 349 start-page: 1 year: 2019 end-page: 54 ident: CR92 article-title: Origin and development of classical dendritic cells publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.08.002 – volume: 72 start-page: 2190 year: 2012 end-page: 2196 ident: CR123 article-title: CD73-deficient mice are resistant to carcinogenesis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-0420 – volume: 17 start-page: 363 year: 2017 end-page: 375 ident: CR44 article-title: Mitochondrial DNA in innate immune responses and inflammatory pathology publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.21 – volume: 15 start-page: 1170 year: 2009 end-page: 1178 ident: CR119 article-title: Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors publication-title: Nat. Med. doi: 10.1038/nm.2028 – volume: 6 start-page: 187 year: 2015 ident: CR209 article-title: Combinatorial strategies for the induction of immunogenic cell death publication-title: Front. Immunol. – volume: 9 start-page: 993 year: 2000 end-page: 997 ident: CR201 article-title: Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin publication-title: Cancer Epidemiol. Biomark. Prev. – volume: 17 start-page: 725 year: 2020 end-page: 741 ident: CR46 article-title: Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0413-z – volume: 12 year: 2020 ident: CR85 article-title: Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201911622 – volume: 341 start-page: 201 year: 2018 end-page: 276 ident: CR65 article-title: T lymphocyte-based cancer immunotherapeutics publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.05.010 – volume: 7 year: 2018 ident: CR72 article-title: Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1446720 – volume: 15 start-page: 477 year: 2018 end-page: 494 ident: CR51 article-title: Safety of combining radiotherapy with immune-checkpoint inhibition publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-018-0046-7 – volume: 348 start-page: 69 year: 2019 end-page: 121 ident: CR22 article-title: Antigen processing and presentation publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.005 – volume: 17 start-page: 611 year: 2020 end-page: 629 ident: CR124 article-title: The adenosine pathway in immuno-oncology publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0382-2 – volume: 350 start-page: 972 year: 2015 end-page: 978 ident: CR125 article-title: Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 publication-title: Science doi: 10.1126/science.aad0779 – volume: 14 start-page: 166 year: 2014 end-page: 180 ident: CR90 article-title: Apoptotic cell clearance: basic biology and therapeutic potential publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3607 – volume: 349 start-page: 177 year: 2019 end-page: 211 ident: CR187 article-title: The versatile plasmacytoid dendritic cell: function, heterogeneity, and plasticity publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.10.002 – volume: 69 start-page: 169 year: 2018 end-page: 181 ident: CR148 article-title: The unfolded protein response and cell fate control publication-title: Mol. Cell doi: 10.1016/j.molcel.2017.06.017 – volume: 24 start-page: 1845 year: 2018 end-page: 1851 ident: CR184 article-title: Radiotherapy induces responses of lung cancer to CTLA-4 blockade publication-title: Nat. Med. doi: 10.1038/s41591-018-0232-2 – volume: 9 start-page: 1754 year: 2019 end-page: 1773 ident: CR176 article-title: Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-19-0541 – volume: 629 start-page: 103 year: 2019 end-page: 113 ident: CR181 article-title: Quinacrine-mediated detection of intracellular ATP publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2019.05.050 – volume: 18 start-page: 313 year: 2018 end-page: 322 ident: CR53 article-title: Using immunotherapy to boost the abscopal effect publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2018.6 – volume: 16 start-page: 619 year: 2016 end-page: 634 ident: CR178 article-title: From Krebs to clinic: glutamine metabolism to cancer therapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.71 – volume: 7 year: 2018 ident: CR188 article-title: Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1404216 – ident: CR170 – volume: 19 start-page: 465 year: 2019 end-page: 478 ident: CR17 article-title: Alternative tumour-specific antigens publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0162-4 – volume: 18 start-page: 845 year: 2019 end-page: 867 ident: CR43 article-title: Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0043-2 – volume: 330 start-page: 115 year: 2017 end-page: 156 ident: CR54 article-title: Rationale for the combination of dendritic cell-based vaccination approaches with chemotherapy agents publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2016.09.003 – volume: 461 start-page: 282 year: 2009 end-page: 286 ident: CR118 article-title: Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance publication-title: Nature doi: 10.1038/nature08296 – volume: 7 start-page: 16 year: 2019 ident: CR60 article-title: A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0464-1 – volume: 21 start-page: S6 issue: Suppl 1 year: 2015 end-page: S12 ident: CR100 article-title: High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule publication-title: Mol. Med. doi: 10.2119/molmed.2015.00087 – volume: 368 start-page: eaat5314 year: 2020 ident: CR147 article-title: The integrated stress response: from mechanism to disease publication-title: Science doi: 10.1126/science.aat5314 – volume: 8 start-page: 1606665 year: 2019 ident: CR206 article-title: A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1606665 – volume: 10 year: 2019 ident: CR79 article-title: Extracorporeal photochemotherapy induces bona fide immunogenic cell death publication-title: Cell Death Dis. doi: 10.1038/s41419-019-1819-3 – volume: 20 start-page: e452 year: 2019 end-page: e463 ident: CR47 article-title: Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30171-8 – volume: 9 start-page: 1721810 year: 2020 ident: CR58 article-title: PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1721810 – volume: 349 start-page: 251 year: 2019 end-page: 307 ident: CR207 article-title: Ex vivo dendritic cell generation-A critical comparison of current approaches publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.10.003 – volume: 15 start-page: 4401 year: 2009 end-page: 4414 ident: CR161 article-title: Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0155 – volume: 414 start-page: 916 year: 2001 end-page: 920 ident: CR122 article-title: Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage publication-title: Nature doi: 10.1038/414916a – volume: 16 start-page: 1093 year: 2009 end-page: 1107 ident: CR113 article-title: Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes publication-title: Cell Death Differ. doi: 10.1038/cdd.2009.44 – volume: 345 start-page: 577266 year: 2020 ident: CR163 article-title: The association between plasma HMGB1 and sRAGE and clinical outcome in intracerebral hemorrhage publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2020.577266 – volume: 2041 start-page: 209 year: 2020 end-page: 221 ident: CR182 article-title: Fluorescent labeling and quantification of vesicular ATP release using live cell imaging publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-9717-6_15 – volume: 31 start-page: 1062 year: 2012 end-page: 1079 ident: CR78 article-title: A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death publication-title: EMBO J. doi: 10.1038/emboj.2011.497 – volume: 9 start-page: 1744947 year: 2020 ident: CR20 article-title: HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1744947 – volume: 7 year: 2016 ident: CR200 article-title: The oncolytic peptide LTX-315 triggers immunogenic cell death publication-title: Cell Death Dis. doi: 10.1038/cddis.2016.47 – volume: 13 start-page: 89 year: 2012 end-page: 102 ident: CR151 article-title: The unfolded protein response: controlling cell fate decisions under ER stress and beyond publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3270 – volume: 17 start-page: 30 year: 2017 end-page: 48 ident: CR29 article-title: Dendritic cell migration in health and disease publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2016.116 – volume: 18 start-page: 498 year: 2018 end-page: 513 ident: CR68 article-title: Integrating oncolytic viruses in combination cancer immunotherapy publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0014-6 – volume: 534 start-page: 119 year: 2014 end-page: 131 ident: CR180 article-title: Assessment of cation trapping by cellular acidic compartments publication-title: Methods Enzymol. doi: 10.1016/B978-0-12-397926-1.00007-X – volume: 125 start-page: 1098 year: 2015 end-page: 1110 ident: CR101 article-title: Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation publication-title: J. Clin. Invest. doi: 10.1172/JCI76344 – volume: 24 start-page: 245 year: 2019 end-page: 255 ident: CR93 article-title: Calreticulin in phagocytosis and cancer: opposite roles in immune response outcomes publication-title: Apoptosis doi: 10.1007/s10495-019-01532-0 – volume: 17 start-page: 595 year: 2020 end-page: 610 ident: CR15 article-title: Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0387-x – volume: 8 start-page: 2067 year: 2002 end-page: 2072 ident: CR202 article-title: Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis publication-title: Clin. Cancer Res. – volume: 4 start-page: 143ra199 year: 2012 ident: CR143 article-title: Cardiac glycosides exert anticancer effects by inducing immunogenic cell death publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3003807 – volume: 344 start-page: 173 year: 2019 end-page: 214 ident: CR129 article-title: Activating the nucleic acid-sensing machinery for anticancer immunity publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.006 – volume: 164 start-page: 65 year: 2015 end-page: 71 ident: CR66 article-title: Reactive oxygen species involved in CT26 immunogenic cell death induced by toxin B publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2015.02.007 – volume: 194 start-page: 4825 year: 2015 end-page: 4835 ident: CR198 article-title: Pattern recognition receptor-initiated innate antiviral responses in mouse epididymal epithelial cells publication-title: J. Immunol. doi: 10.4049/jimmunol.1402706 – volume: 29 start-page: 396 year: 2019 end-page: 416 ident: CR18 article-title: Mutational and antigenic landscape in tumor progression and cancer immunotherapy publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2019.01.003 – volume: 323 start-page: 113072 year: 2020 ident: CR144 article-title: Mechanism and role of the intra-axonal Calreticulin translation in response to axonal injury publication-title: Exp. Neurol. doi: 10.1016/j.expneurol.2019.113072 – volume: 25 start-page: 1375 year: 2018 end-page: 1393 ident: CR149 article-title: eIF2α phosphorylation is pathognomonic for immunogenic cell death publication-title: Cell Death Differ. doi: 10.1038/s41418-017-0044-9 – volume: 21 start-page: 963 year: 2020 end-page: 965 ident: CR150 article-title: XBP-1 and the unfolded protein response (UPR) publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0708-3 – volume: 3 start-page: 373 year: 2008 end-page: 382 ident: CR142 article-title: HaloTag: a novel protein labeling technology for cell imaging and protein analysis publication-title: ACS Chem. Biol. doi: 10.1021/cb800025k – volume: 21 start-page: 79 year: 2014 end-page: 91 ident: CR114 article-title: Molecular mechanisms of ATP secretion during immunogenic cell death publication-title: Cell Death Differ. doi: 10.1038/cdd.2013.75 – volume: 14 year: 2018 ident: CR138 article-title: Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006985 – volume: 13 start-page: 1050 year: 2007 end-page: 1059 ident: CR103 article-title: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy publication-title: Nat. Med. doi: 10.1038/nm1622 – volume: 18 start-page: 669 year: 2019 end-page: 688 ident: CR177 article-title: Targeting metabolism to regulate immune responses in autoimmunity and cancer publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0032-5 – volume: 17 start-page: 275 year: 2012 end-page: 279 ident: CR155 article-title: A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress publication-title: Cell Stress Chaperones doi: 10.1007/s12192-011-0306-2 – volume: 21 start-page: 501 year: 2020 end-page: 521 ident: CR130 article-title: Molecular mechanisms and cellular functions of cGAS-STING signalling publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-020-0244-x – volume: 405 start-page: 354 year: 2000 end-page: 360 ident: CR104 article-title: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases publication-title: Nature doi: 10.1038/35012626 – volume: 344 start-page: 31 year: 2019 end-page: 89 ident: CR128 article-title: Intracellular RNA sensing in mammalian cells: role in stress response and cancer therapies publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.005 – volume: 45 year: 2017 ident: CR204 article-title: Analysis of translation using polysome profiling publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkw1005 – volume: 2 year: 2013 ident: CR28 article-title: Trial watch: dendritic cell-based interventions for cancer therapy publication-title: Oncoimmunology doi: 10.4161/onci.25771 – volume: 21 start-page: 1160 year: 2020 end-page: 1171 ident: CR89 article-title: Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0751-0 – volume: 20 start-page: 7 year: 2020 end-page: 24 ident: CR208 article-title: Dendritic cells in cancer immunology and immunotherapy publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0210-z – volume: 20 start-page: 1301 year: 2014 end-page: 1309 ident: CR126 article-title: Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy publication-title: Nat. Med. doi: 10.1038/nm.3708 – volume: 6 year: 2016 ident: CR197 article-title: Mumps virus-induced innate immune responses in mouse Sertoli and Leydig cells publication-title: Sci. Rep. doi: 10.1038/srep19507 – volume: 23 start-page: 4854 year: 2019 end-page: 4865 ident: CR39 article-title: Immunogenic cell death in cancer therapy: present and emerging inducers publication-title: J. Cell Mol. Med. doi: 10.1111/jcmm.14356 – volume: 58 start-page: 1754 year: 2019 end-page: 1769 ident: CR116 article-title: Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma publication-title: Mol. Carcinog. doi: 10.1002/mc.23050 – volume: 589 start-page: 351 year: 2017 end-page: 364 ident: CR172 article-title: A highly sensitive biosensor for ATP using a chimeric firefly luciferase publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2017.01.004 – volume: 22 start-page: 624 year: 2016 end-page: 631 ident: CR74 article-title: The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death publication-title: Nat. Med. doi: 10.1038/nm.4078 – volume: 9 start-page: 722 year: 2019 end-page: 737 ident: CR76 article-title: PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1218 – volume: 8 start-page: e000337 year: 2020 ident: CR16 article-title: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2019-000337 – volume: 4 year: 2015 ident: CR50 article-title: Trial Watch: immunogenic cell death inducers for anticancer chemotherapy publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1008866 – volume: 19 start-page: 307 year: 2019 end-page: 325 ident: CR5 article-title: Tertiary lymphoid structures in the era of cancer immunotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0144-6 – volume: 342 start-page: 1 year: 2019 end-page: 25 ident: CR62 article-title: Stimulating T cells against cancer with agonist immunostimulatory monoclonal antibodies publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.07.003 – volume: 123 start-page: 321 year: 2005 end-page: 334 ident: CR95 article-title: Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte publication-title: Cell doi: 10.1016/j.cell.2005.08.032 – volume: 356 start-page: 195 year: 2007 end-page: 208 ident: CR141 article-title: The HaloTag: a novel technology for cell imaging and protein analysis publication-title: Methods Mol. Biol. – volume: 10 year: 2020 ident: CR195 article-title: The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent publication-title: Sci. Rep. doi: 10.1038/s41598-020-64865-w – volume: 9 start-page: 496 year: 2018 ident: CR136 article-title: Type I interferon-independent dendritic cell priming and antitumor T cell activation induced by a lipopeptide publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.00496 – volume: 77 start-page: 1653 year: 2018 end-page: 1664 ident: CR193 article-title: Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2018-213197 – volume: 4 year: 2013 ident: CR31 article-title: Many faces of DAMPs in cancer therapy publication-title: Cell Death Dis. doi: 10.1038/cddis.2013.156 – volume: 17 year: 2019 ident: CR145 article-title: Reticulon and CLIMP-63 regulate nanodomain organization of peripheral ER tubules publication-title: PLoS Biol. doi: 10.1371/journal.pbio.3000355 – ident: CR175 – volume: 39 start-page: 11 year: 2013 end-page: 26 ident: CR6 article-title: The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures publication-title: Immunity doi: 10.1016/j.immuni.2013.07.008 – volume: 8 year: 2019 ident: CR81 article-title: Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1523097 – volume: 34 start-page: 361 year: 2018 end-page: 378 ident: CR83 article-title: Cytosolic DNA sensing in organismal tumor control publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.05.013 – volume: 377 start-page: 319 year: 2008 end-page: 329 ident: CR199 article-title: Expression profile of interferon stimulated genes in central nervous system of mice infected with dengue virus Type-1 publication-title: Virology doi: 10.1016/j.virol.2008.04.033 – volume: 20 start-page: 243 year: 2018 end-page: 251 ident: CR88 article-title: The autophagic network and cancer publication-title: Nat. Cell Biol. doi: 10.1038/s41556-018-0042-2 – volume: 9 start-page: 493 year: 2012 end-page: 498 ident: CR169 article-title: Synchronization of secretory protein traffic in populations of cells publication-title: Nat. Methods doi: 10.1038/nmeth.1928 – volume: 21 start-page: 137 year: 2004 end-page: 148 ident: CR12 article-title: The immunobiology of cancer immunosurveillance and immunoediting publication-title: Immunity doi: 10.1016/j.immuni.2004.07.017 – volume: 20 start-page: 665 year: 2019 end-page: 680 ident: CR84 article-title: The Hsp70 chaperone network publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-019-0133-3 – volume: 14 start-page: 546 year: 2014 end-page: 558 ident: CR107 article-title: Assembly and localization of Toll-like receptor signalling complexes publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3713 – volume: 8 year: 2019 ident: CR112 article-title: Trial watch: dendritic cell vaccination for cancer immunotherapy publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1638212 – volume: 72 start-page: 3967 year: 2012 end-page: 3976 ident: CR166 article-title: Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-0851 – volume: 19 start-page: 477 year: 2019 end-page: 489 ident: CR121 article-title: The NLRP3 inflammasome: molecular activation and regulation to therapeutics publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0165-0 – volume: 105 start-page: 1868 year: 2020 end-page: 1878 ident: CR98 article-title: Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients publication-title: Haematologica doi: 10.3324/haematol.2019.223933 – volume: 135 start-page: 1165 year: 2014 end-page: 1177 ident: CR80 article-title: High hydrostatic pressure induces immunogenic cell death in human tumor cells publication-title: Int. J. Cancer doi: 10.1002/ijc.28766 – volume: 41 start-page: 843 year: 2014 end-page: 852 ident: CR140 article-title: STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors publication-title: Immunity doi: 10.1016/j.immuni.2014.10.019 – volume: 8 year: 2019 ident: CR135 article-title: Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1570779 – volume: 348 start-page: 1 year: 2019 end-page: 68 ident: CR33 article-title: Dendritic cell subsets and locations publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.004 – volume: 117 start-page: 3352 year: 2020 end-page: 3354 ident: CR152 article-title: Dynamics and clustering of IRE1alpha during ER stress publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1921799117 – volume: 9 start-page: 293 year: 2010 end-page: 307 ident: CR212 article-title: Targeting Toll-like receptors: emerging therapeutics? publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3203 – volume: 18 start-page: 601 year: 2018 end-page: 618 ident: CR82 article-title: Extracellular ATP and P2 purinergic signalling in the tumour microenvironment publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-018-0037-0 – volume: 282 start-page: 34525 year: 2007 end-page: 34534 ident: CR156 article-title: The role of brain-derived neurotrophic factor (BDNF)-induced XBP1 splicing during brain development publication-title: J. Biol. Chem. doi: 10.1074/jbc.M704300200 – volume: 12 start-page: 58 year: 2011 end-page: 67 ident: CR211 article-title: Programmed cell removal: a new obstacle in the road to developing cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3171 – volume: 7 year: 2018 ident: CR71 article-title: PKR and GCN2 stress kinases promote an ER stress-independent eIF2alpha phosphorylation responsible for calreticulin exposure in melanoma cells publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1466765 – volume: 7 start-page: 584 year: 2019 end-page: 599 ident: CR134 article-title: Sustained type I interferon reinforces NK cell-mediated cancer immunosurveillance during chronic virus infection publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0403 – volume: 3 year: 2014 ident: CR64 article-title: Trial Watch: immunostimulatory monoclonal antibodies in cancer therapy publication-title: Oncoimmunology doi: 10.4161/onci.27297 – volume: 6 start-page: 910 year: 2018 end-page: 920 ident: CR189 article-title: Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs publication-title: Cancer Immunol. Res doi: 10.1158/2326-6066.CIR-17-0581 – volume: 19 start-page: 568 year: 2019 end-page: 586 ident: CR210 article-title: Phagocytosis checkpoints as new targets for cancer immunotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0183-z – volume: 334 start-page: 1573 year: 2011 end-page: 1577 ident: CR86 article-title: Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice publication-title: Science doi: 10.1126/science.1208347 – volume: 20 start-page: 1301 year: 2014 ident: 3221_CR126 publication-title: Nat. Med. doi: 10.1038/nm.3708 – volume: 105 start-page: 1868 year: 2020 ident: 3221_CR98 publication-title: Haematologica doi: 10.3324/haematol.2019.223933 – volume: 17 start-page: 611 year: 2020 ident: 3221_CR124 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0382-2 – volume: 23 start-page: 4854 year: 2019 ident: 3221_CR39 publication-title: J. Cell Mol. Med. doi: 10.1111/jcmm.14356 – volume: 17 start-page: 363 year: 2017 ident: 3221_CR44 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.21 – volume: 18 start-page: 601 year: 2018 ident: 3221_CR82 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-018-0037-0 – volume: 11 year: 2020 ident: 3221_CR25 publication-title: Nat. Commun. doi: 10.1038/s41467-020-15726-7 – volume: 4 start-page: 143ra199 year: 2012 ident: 3221_CR143 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3003807 – volume: 18 start-page: 313 year: 2018 ident: 3221_CR53 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2018.6 – volume: 190 start-page: 5207 year: 2013 ident: 3221_CR97 publication-title: J. Immunol. doi: 10.4049/jimmunol.1300057 – volume: 164 start-page: 65 year: 2015 ident: 3221_CR66 publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2015.02.007 – volume: 14 start-page: 166 year: 2014 ident: 3221_CR90 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3607 – volume: 349 start-page: 251 year: 2019 ident: 3221_CR207 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.10.003 – volume: 20 start-page: 7 year: 2013 ident: 3221_CR67 publication-title: Gene Ther. doi: 10.1038/gt.2011.205 – volume: 8 year: 2019 ident: 3221_CR135 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1570779 – ident: 3221_CR170 doi: 10.1002/0471143030.cb1519s57 – volume: 348 start-page: 69 year: 2019 ident: 3221_CR22 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.005 – volume: 151 start-page: 764 year: 2019 ident: 3221_CR203 publication-title: J. Neurochem. doi: 10.1111/jnc.14874 – volume: 21 start-page: S6 issue: Suppl 1 year: 2015 ident: 3221_CR100 publication-title: Mol. Med. doi: 10.2119/molmed.2015.00087 – volume: 28 start-page: 578 year: 2009 ident: 3221_CR94 publication-title: EMBO J. doi: 10.1038/emboj.2009.1 – volume: 58 start-page: 1754 year: 2019 ident: 3221_CR116 publication-title: Mol. Carcinog. doi: 10.1002/mc.23050 – volume: 8 year: 2019 ident: 3221_CR112 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1638212 – volume: 6 start-page: 402 year: 2015 ident: 3221_CR45 publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00402 – volume: 15 start-page: 477 year: 2018 ident: 3221_CR51 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-018-0046-7 – volume: 9 start-page: 1721810 year: 2020 ident: 3221_CR58 publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1721810 – volume: 10 year: 2020 ident: 3221_CR195 publication-title: Sci. Rep. doi: 10.1038/s41598-020-64865-w – volume: 117 start-page: 3352 year: 2020 ident: 3221_CR152 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1921799117 – volume: 368 start-page: eaat5314 year: 2020 ident: 3221_CR147 publication-title: Science doi: 10.1126/science.aat5314 – volume: 123 start-page: 321 year: 2005 ident: 3221_CR95 publication-title: Cell doi: 10.1016/j.cell.2005.08.032 – volume: 13 year: 2017 ident: 3221_CR192 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006326 – volume: 10 year: 2019 ident: 3221_CR79 publication-title: Cell Death Dis. doi: 10.1038/s41419-019-1819-3 – volume: 34 start-page: 177 year: 2011 ident: 3221_CR186 publication-title: Diabetes Care doi: 10.2337/dc10-1219 – volume: 3 start-page: 373 year: 2008 ident: 3221_CR142 publication-title: ACS Chem. Biol. doi: 10.1021/cb800025k – volume: 15 start-page: 4401 year: 2009 ident: 3221_CR161 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0155 – volume: 41 start-page: 843 year: 2014 ident: 3221_CR140 publication-title: Immunity doi: 10.1016/j.immuni.2014.10.019 – volume: 12 start-page: 703 year: 2013 ident: 3221_CR153 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3976 – volume: 29 start-page: 44 year: 2019 ident: 3221_CR3 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2018.08.005 – volume: 19 start-page: 215 year: 2019 ident: 3221_CR4 publication-title: Nat. Rev. Cancer – volume: 342 start-page: 1 year: 2019 ident: 3221_CR62 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.07.003 – volume: 342 start-page: 149 year: 2019 ident: 3221_CR11 publication-title: Int Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.001 – volume: 14 start-page: 546 year: 2014 ident: 3221_CR107 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3713 – volume: 9 start-page: 1754 year: 2019 ident: 3221_CR176 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-19-0541 – volume: 4 year: 2013 ident: 3221_CR31 publication-title: Cell Death Dis. doi: 10.1038/cddis.2013.156 – volume: 19 start-page: 477 year: 2019 ident: 3221_CR121 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0165-0 – volume: 8 year: 2019 ident: 3221_CR81 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1523097 – volume: 194 start-page: 4825 year: 2015 ident: 3221_CR198 publication-title: J. Immunol. doi: 10.4049/jimmunol.1402706 – volume: 6 start-page: 836 year: 2006 ident: 3221_CR10 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri1961 – volume: 344 start-page: 1 year: 2019 ident: 3221_CR133 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.004 – volume: 20 start-page: 7 year: 2020 ident: 3221_CR208 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0210-z – volume: 10 year: 2009 ident: 3221_CR190 publication-title: BMC Genomics doi: 10.1186/1471-2164-10-365 – volume: 16 start-page: 1093 year: 2009 ident: 3221_CR113 publication-title: Cell Death Differ. doi: 10.1038/cdd.2009.44 – volume: 45 start-page: 159 year: 2017 ident: 3221_CR165 publication-title: Urolithiasis doi: 10.1007/s00240-016-0902-9 – volume: 29 start-page: 396 year: 2019 ident: 3221_CR18 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2019.01.003 – volume: 377 start-page: 1919 year: 2017 ident: 3221_CR56 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709937 – volume: 4 year: 2015 ident: 3221_CR50 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1008866 – volume: 118 start-page: 312 year: 2018 ident: 3221_CR55 publication-title: Br. J. Cancer doi: 10.1038/bjc.2017.376 – volume: 440 start-page: 228 year: 2006 ident: 3221_CR120 publication-title: Nature doi: 10.1038/nature04515 – volume: 13 start-page: 89 year: 2012 ident: 3221_CR151 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3270 – volume: 349 start-page: 55 year: 2019 ident: 3221_CR30 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.10.001 – volume: 7 year: 2018 ident: 3221_CR105 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1526250 – volume: 20 start-page: 665 year: 2019 ident: 3221_CR84 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-019-0133-3 – volume: 20 start-page: 243 year: 2018 ident: 3221_CR88 publication-title: Nat. Cell Biol. doi: 10.1038/s41556-018-0042-2 – volume: 8 year: 2017 ident: 3221_CR139 publication-title: Nat. Commun. doi: 10.1038/ncomms15618 – volume: 8 year: 2019 ident: 3221_CR127 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1655964 – volume: 397 start-page: 271 year: 1999 ident: 3221_CR154 publication-title: Nature doi: 10.1038/16729 – volume: 18 start-page: 197 year: 2019 ident: 3221_CR52 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0007-y – volume: 20 start-page: 25 year: 2020 ident: 3221_CR24 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0218-4 – volume: 7 year: 2018 ident: 3221_CR71 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1466765 – volume: 7 year: 2018 ident: 3221_CR72 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1446720 – volume: 8 year: 2019 ident: 3221_CR109 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1667743 – volume: 414 start-page: 916 year: 2001 ident: 3221_CR122 publication-title: Nature doi: 10.1038/414916a – volume: 77 start-page: 1653 year: 2018 ident: 3221_CR193 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2018-213197 – volume: 323 start-page: 113072 year: 2020 ident: 3221_CR144 publication-title: Exp. Neurol. doi: 10.1016/j.expneurol.2019.113072 – volume: 72 start-page: 3967 year: 2012 ident: 3221_CR166 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-0851 – volume: 66 start-page: 47 year: 1975 ident: 3221_CR173 publication-title: Anal. Biochem. doi: 10.1016/0003-2697(75)90723-X – volume: 629 start-page: 177 year: 2019 ident: 3221_CR160 publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2019.05.001 – volume: 18 start-page: 168 year: 2018 ident: 3221_CR19 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.131 – volume: 2 start-page: 253 year: 1998 ident: 3221_CR106 publication-title: Mol. Cell doi: 10.1016/S1097-2765(00)80136-7 – volume: 348 start-page: 1 year: 2019 ident: 3221_CR33 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.004 – volume: 349 start-page: 177 year: 2019 ident: 3221_CR187 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.10.002 – volume: 9 start-page: 993 year: 2000 ident: 3221_CR201 publication-title: Cancer Epidemiol. Biomark. Prev. – volume: 18 start-page: 669 year: 2019 ident: 3221_CR177 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0032-5 – volume: 290 start-page: C917 year: 2006 ident: 3221_CR102 publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00401.2005 – volume: 25 start-page: 1375 year: 2018 ident: 3221_CR149 publication-title: Cell Death Differ. doi: 10.1038/s41418-017-0044-9 – volume: 377 start-page: 319 year: 2008 ident: 3221_CR199 publication-title: Virology doi: 10.1016/j.virol.2008.04.033 – volume: 90 start-page: 1 year: 2006 ident: 3221_CR1 publication-title: Adv. Immunol. doi: 10.1016/S0065-2776(06)90001-7 – volume: 12 start-page: 58 year: 2011 ident: 3221_CR211 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3171 – volume: 23 start-page: 1882 year: 2018 ident: 3221_CR167 publication-title: J. BUON – volume: 24 start-page: 1845 year: 2018 ident: 3221_CR184 publication-title: Nat. Med. doi: 10.1038/s41591-018-0232-2 – volume: 344 start-page: 31 year: 2019 ident: 3221_CR128 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.005 – volume: 19 start-page: 307 year: 2019 ident: 3221_CR5 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0144-6 – volume: 24 start-page: 319 year: 2013 ident: 3221_CR69 publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2013.01.005 – volume: 46 start-page: 811 year: 2020 ident: 3221_CR164 publication-title: Intensive Care Med. doi: 10.1007/s00134-020-05941-7 – volume: 629 start-page: 103 year: 2019 ident: 3221_CR181 publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2019.05.050 – volume: 7 year: 2018 ident: 3221_CR49 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1471440 – volume: 2041 start-page: 209 year: 2020 ident: 3221_CR182 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-9717-6_15 – volume: 21 start-page: 1160 year: 2020 ident: 3221_CR89 publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0751-0 – volume: 17 start-page: 262 year: 2017 ident: 3221_CR37 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.9 – volume: 24 start-page: 245 year: 2019 ident: 3221_CR93 publication-title: Apoptosis doi: 10.1007/s10495-019-01532-0 – volume: 8 year: 2019 ident: 3221_CR108 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1641391 – volume: 7 start-page: 584 year: 2019 ident: 3221_CR134 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0403 – volume: 7 year: 2018 ident: 3221_CR87 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1431089 – volume: 69 start-page: 169 year: 2018 ident: 3221_CR148 publication-title: Mol. Cell doi: 10.1016/j.molcel.2017.06.017 – volume: 72 start-page: 2190 year: 2012 ident: 3221_CR123 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-0420 – volume: 18 start-page: 545 year: 2018 ident: 3221_CR13 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0029-z – volume: 30 start-page: 596 year: 2007 ident: 3221_CR159 publication-title: J. Immunother. doi: 10.1097/CJI.0b013e31804efc76 – volume: 18 start-page: 498 year: 2018 ident: 3221_CR68 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0014-6 – volume: 22 start-page: 155 year: 2013 ident: 3221_CR185 publication-title: Lupus doi: 10.1177/0961203312468964 – volume: 7 start-page: 312 year: 2019 ident: 3221_CR91 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0781-z – volume: 8 start-page: 2067 year: 2002 ident: 3221_CR202 publication-title: Clin. Cancer Res. – volume: 9 start-page: 1744947 year: 2020 ident: 3221_CR20 publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1744947 – volume: 25 start-page: 920 year: 2019 ident: 3221_CR57 publication-title: Nat. Med. doi: 10.1038/s41591-019-0432-4 – volume: 5 year: 2014 ident: 3221_CR157 publication-title: Nat. Commun. doi: 10.1038/ncomms4554 – volume: 348 start-page: 217 year: 2019 ident: 3221_CR32 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.06.001 – volume: 9 start-page: 1710398 year: 2020 ident: 3221_CR48 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1710398 – volume: 17 year: 2019 ident: 3221_CR145 publication-title: PLoS Biol. doi: 10.1371/journal.pbio.3000355 – volume: 20 start-page: 95 year: 2020 ident: 3221_CR34 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0215-7 – volume: 3 year: 2014 ident: 3221_CR61 publication-title: Oncoimmunology doi: 10.4161/onci.27878 – volume: 341 start-page: 201 year: 2018 ident: 3221_CR65 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.05.010 – volume: 125 start-page: 1098 year: 2015 ident: 3221_CR101 publication-title: J. Clin. Invest. doi: 10.1172/JCI76344 – volume: 7 year: 2018 ident: 3221_CR188 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1404216 – volume: 7 start-page: 50 year: 2019 ident: 3221_CR70 publication-title: Front. Cell Dev. Biol. doi: 10.3389/fcell.2019.00050 – volume: 10 year: 2019 ident: 3221_CR59 publication-title: Nat. Commun. doi: 10.1038/s41467-019-09415-3 – volume: 18 start-page: 219 year: 2019 ident: 3221_CR183 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0011-2 – volume: 19 start-page: 568 year: 2019 ident: 3221_CR210 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0183-z – volume: 341 start-page: 1 year: 2018 ident: 3221_CR8 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.07.002 – volume: 30 start-page: 261 year: 2018 ident: 3221_CR168 publication-title: Iran. J. Otorhinolaryngol. – volume: 135 start-page: 1165 year: 2014 ident: 3221_CR80 publication-title: Int. J. Cancer doi: 10.1002/ijc.28766 – volume: 87 start-page: 51164 year: 2014 ident: 3221_CR205 publication-title: J. Vis. Exp. – volume: 534 start-page: 119 year: 2014 ident: 3221_CR180 publication-title: Methods Enzymol. doi: 10.1016/B978-0-12-397926-1.00007-X – volume: 9 year: 2018 ident: 3221_CR194 publication-title: Nat. Commun. doi: 10.1038/s41467-018-03555-8 – volume: 334 start-page: 1573 year: 2011 ident: 3221_CR86 publication-title: Science doi: 10.1126/science.1208347 – volume: 21 start-page: 120 year: 2020 ident: 3221_CR77 publication-title: Nat. Immunol. doi: 10.1038/s41590-019-0561-4 – volume: 6 start-page: 187 year: 2015 ident: 3221_CR209 publication-title: Front. Immunol. – volume: 6 start-page: 910 year: 2018 ident: 3221_CR189 publication-title: Cancer Immunol. Res doi: 10.1158/2326-6066.CIR-17-0581 – volume: 527 start-page: 249 year: 2015 ident: 3221_CR9 publication-title: Nature doi: 10.1038/nature15520 – volume: 45 year: 2017 ident: 3221_CR204 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkw1005 – volume: 356 start-page: 195 year: 2007 ident: 3221_CR141 publication-title: Methods Mol. Biol. – volume: 13 start-page: 95 year: 2015 ident: 3221_CR35 publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro3390 – volume: 15 start-page: 1170 year: 2009 ident: 3221_CR119 publication-title: Nat. Med. doi: 10.1038/nm.2028 – volume: 9 start-page: 293 year: 2010 ident: 3221_CR212 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3203 – volume: 39 start-page: 11 year: 2013 ident: 3221_CR6 publication-title: Immunity doi: 10.1016/j.immuni.2013.07.008 – volume: 581 start-page: 100 year: 2020 ident: 3221_CR23 publication-title: Nature doi: 10.1038/s41586-020-2229-5 – volume: 405 start-page: 354 year: 2000 ident: 3221_CR104 publication-title: Nature doi: 10.1038/35012626 – volume: 461 start-page: 282 year: 2009 ident: 3221_CR118 publication-title: Nature doi: 10.1038/nature08296 – volume: 21 start-page: 501 year: 2020 ident: 3221_CR130 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-020-0244-x – volume: 347 start-page: 191 year: 2019 ident: 3221_CR179 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.003 – volume: 350 start-page: 972 year: 2015 ident: 3221_CR125 publication-title: Science doi: 10.1126/science.aad0779 – volume: 589 start-page: 351 year: 2017 ident: 3221_CR172 publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2017.01.004 – volume: 8 start-page: 1606665 year: 2019 ident: 3221_CR206 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1606665 – volume: 21 start-page: 398 year: 2020 ident: 3221_CR41 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-020-0232-1 – volume: 187 start-page: 4954 year: 2011 ident: 3221_CR73 publication-title: J. Immunol. doi: 10.4049/jimmunol.1003477 – volume: 9 year: 2011 ident: 3221_CR110 publication-title: J. Transl. Med. doi: 10.1186/1479-5876-9-139 – volume: 14 year: 2018 ident: 3221_CR138 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006985 – volume: 8 year: 2017 ident: 3221_CR21 publication-title: Nat. Commun. doi: 10.1038/s41467-017-01062-w – volume: 87 start-page: 659 year: 2007 ident: 3221_CR117 publication-title: Physiol. Rev. doi: 10.1152/physrev.00043.2006 – volume: 349 start-page: 1 year: 2019 ident: 3221_CR92 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.08.002 – volume: 31 start-page: 1062 year: 2012 ident: 3221_CR78 publication-title: EMBO J. doi: 10.1038/emboj.2011.497 – volume: 348 start-page: 69 year: 2015 ident: 3221_CR14 publication-title: Science doi: 10.1126/science.aaa4971 – volume: 348 start-page: 123 year: 2019 ident: 3221_CR26 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.006 – volume: 34 start-page: 361 year: 2018 ident: 3221_CR83 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.05.013 – volume: 12 year: 2020 ident: 3221_CR85 publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201911622 – volume: 330 start-page: 115 year: 2017 ident: 3221_CR54 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2016.09.003 – volume: 7 start-page: 16 year: 2019 ident: 3221_CR60 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0464-1 – volume: 3 year: 2014 ident: 3221_CR64 publication-title: Oncoimmunology doi: 10.4161/onci.27297 – volume: 19 start-page: 465 year: 2019 ident: 3221_CR17 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0162-4 – volume: 20 start-page: 657 year: 2019 ident: 3221_CR132 publication-title: Nat. Rev. Genet. doi: 10.1038/s41576-019-0151-1 – volume: 9 start-page: 496 year: 2018 ident: 3221_CR136 publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.00496 – volume: 13 start-page: 1050 year: 2007 ident: 3221_CR103 publication-title: Nat. Med. doi: 10.1038/nm1622 – volume: 305 start-page: 346 year: 2000 ident: 3221_CR174 publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(00)05499-9 – volume: 344 start-page: 173 year: 2019 ident: 3221_CR129 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2018.08.006 – ident: 3221_CR175 doi: 10.1038/s41375-020-0788-y – volume: 112 start-page: 15408 year: 2015 ident: 3221_CR196 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1512832112 – volume: 17 start-page: 595 year: 2020 ident: 3221_CR15 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0387-x – volume: 7 year: 2016 ident: 3221_CR200 publication-title: Cell Death Dis. doi: 10.1038/cddis.2016.47 – volume: 20 start-page: 203 year: 2020 ident: 3221_CR131 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-020-0246-1 – volume: 1805 start-page: 53 year: 2010 ident: 3221_CR40 publication-title: Biochim. Biophys. Acta – volume: 21 start-page: 137 year: 2004 ident: 3221_CR12 publication-title: Immunity doi: 10.1016/j.immuni.2004.07.017 – volume: 23 start-page: 3499 year: 2012 ident: 3221_CR158 publication-title: Mol. Biol. Cell doi: 10.1091/mbc.e12-05-0385 – volume: 16 start-page: 619 year: 2016 ident: 3221_CR178 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.71 – volume: 331 start-page: 1565 year: 2011 ident: 3221_CR2 publication-title: Science doi: 10.1126/science.1203486 – volume: 8 start-page: e000337 year: 2020 ident: 3221_CR16 publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2019-000337 – volume: 282 start-page: 34525 year: 2007 ident: 3221_CR156 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M704300200 – volume: 17 start-page: 30 year: 2017 ident: 3221_CR29 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2016.116 – volume: 345 start-page: 577266 year: 2020 ident: 3221_CR163 publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2020.577266 – volume: 61 start-page: 2067 year: 2012 ident: 3221_CR111 publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-012-1268-7 – volume: 128 start-page: 3113 year: 2016 ident: 3221_CR99 publication-title: Blood doi: 10.1182/blood-2016-08-731737 – volume: 115 start-page: 13 year: 2003 ident: 3221_CR96 publication-title: Cell doi: 10.1016/S0092-8674(03)00758-X – volume: 19 start-page: 698 year: 2019 ident: 3221_CR7 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0210-0 – volume: 17 start-page: 275 year: 2012 ident: 3221_CR155 publication-title: Cell Stress Chaperones doi: 10.1007/s12192-011-0306-2 – volume: 22 start-page: 624 year: 2016 ident: 3221_CR74 publication-title: Nat. Med. doi: 10.1038/nm.4078 – volume: 8 start-page: 1591875 year: 2019 ident: 3221_CR162 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1591875 – volume: 17 start-page: 725 year: 2020 ident: 3221_CR46 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0413-z – volume: 629 start-page: 81 year: 2019 ident: 3221_CR171 publication-title: Methods Enzymol. doi: 10.1016/bs.mie.2019.10.006 – volume: 76 start-page: 1746 year: 2016 ident: 3221_CR146 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-1142 – volume: 348 start-page: 179 year: 2019 ident: 3221_CR27 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.07.008 – volume: 19 start-page: 141 year: 2019 ident: 3221_CR42 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0117-0 – volume: 20 start-page: e452 year: 2019 ident: 3221_CR47 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30171-8 – volume: 12 start-page: 860 year: 2012 ident: 3221_CR38 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3380 – volume: 347 start-page: 145 year: 2019 ident: 3221_CR115 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/bs.ircmb.2019.06.002 – volume: 18 start-page: 845 year: 2019 ident: 3221_CR43 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0043-2 – volume: 2 year: 2013 ident: 3221_CR28 publication-title: Oncoimmunology doi: 10.4161/onci.25771 – volume: 9 start-page: 722 year: 2019 ident: 3221_CR76 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1218 – volume: 129 start-page: 1211 year: 2019 ident: 3221_CR75 publication-title: J. Clin. Invest. doi: 10.1172/JCI123319 – volume: 165 start-page: 535 year: 2016 ident: 3221_CR191 publication-title: Cell doi: 10.1016/j.cell.2016.03.014 – volume: 17 start-page: 854 year: 2018 ident: 3221_CR63 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.210 – volume: 21 start-page: 963 year: 2020 ident: 3221_CR150 publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0708-3 – volume: 9 start-page: 493 year: 2012 ident: 3221_CR169 publication-title: Nat. Methods doi: 10.1038/nmeth.1928 – volume: 15 start-page: 87 year: 2015 ident: 3221_CR36 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3787 – volume: 21 start-page: 79 year: 2014 ident: 3221_CR114 publication-title: Cell Death Differ. doi: 10.1038/cdd.2013.75 – volume: 6 year: 2016 ident: 3221_CR197 publication-title: Sci. Rep. doi: 10.1038/srep19507 – volume: 8 start-page: 1383 year: 2017 ident: 3221_CR137 publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.01383
SSID	ssj0000330256
Score	2.7040393
SecondaryResourceType	review_article
Snippet	Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely... Abstract Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which...
SourceID	doaj pubmedcentral hal proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1013
SubjectTerms	631/154 631/250/1932 631/67/1059/2325 Adjuvanticity Antibodies Antigen-presenting cells Antigenicity Antineoplastic drugs Antitumor agents Apoptosis Autophagy Biochemistry Biomedical and Life Sciences Calreticulin Cancer Cancer therapies Cell activation Cell Biology Cell Culture Cell death Chemotherapy Drug Discovery - methods HMGB1 protein Humans Immune response Immunogenic Cell Death - immunology Immunogenicity Immunology Immunotherapy - methods Initiation factor eIF-2 Interferon Life Sciences Neoplasms - therapy Phagocytosis Phosphorylation Radiation therapy Review Review Article Transcription
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQBRIXBOUVWiqDuEHUOLYT-1go1R5QxQGk3qz4pUZC2Wo3rdR_3xk7uzRUwKW33djZWPPIfN_aM0PIh6ik00F1peiCLUXkurSNdWUDhKhSOgrvc7OJ9vRUnZ3p77dafeGZsFweOAvuUEurLOct0zYKEVvlvZaVB_LjlJfK4dsXUM8tMpXewUDTIZhPWTIVV4drwQTm6wBbqsCIWVnPIlEq2A_x5RyPQ97FmnePTP6xb5rC0clT8mTCkfQor_8ZeRCGXfIod5a8fk4Wx2FMh6wGuoy0xySQJZhK7yj-U089Aj_aDZ7245pi35R0EoACgqUOP61oTsy6fkF-nnz98WVRTk0TSgdxZyyl8I61MXANXxnSBS494izhFG6Bdlp7BzzPWuA6XjolNMbxCEDCQWiy_CXZGZZDeE2o9V5WTeeBtAQh2qZj0dfS6tg41UHoLwjbCNC4qaI4Nrb4ZdLONlcmC92A0E0SuqkL8nF7z0Wup_HP2Z9RL9uZWAs7XQALMZOFmP9ZSEHeg1Znv7E4-mbwGu4vCa3YFSvI_kbpZvLitalFyxH_1TD8bjsM_oeq6oawvMQ5mJ0LpA_E8SrbyPZRHNAq6EEXpJ1Zz2wt85GhP081vttGAxaDOz9t7Oz3sv4urzf3Ia898rhGN2HgI80-2RlXl-Eteeiuxn69Okh-dgMCsiag priority: 102 providerName: Directory of Open Access Journals
Title	Detection of immunogenic cell death and its relevance for cancer therapy
URI	https://link.springer.com/article/10.1038/s41419-020-03221-2 https://www.ncbi.nlm.nih.gov/pubmed/33243969 https://www.proquest.com/docview/2473251221 https://www.proquest.com/docview/2465437534 https://hal.sorbonne-universite.fr/hal-03094981 https://pubmed.ncbi.nlm.nih.gov/PMC7691519 https://doaj.org/article/95b8b33719bf44f78dd950d978c8d58c
Volume	11
WOSCitedRecordID	wos000595956300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: M2P dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-xFqS98P0RGJVBvEG0OHFi-wltsKlIrKoQSOXJiu2EVULJ1naT9t9z56SdysReeLHaxGmT3Nn3u2-Ad7XKna5UGYuysrGoMx3bwrq4QIUoUboW3nfNJuRkomYzPe0Nbss-rHK9J4aN2reObOT7qZAZyeKUfzw7j6lrFHlX-xYaOzCkSmViAMPDo8n028bKkqC6jkK9z5ZJMrW_FFxQ3g5qTQkyM4_TLYkUCvejnDmlsMibmPNm6ORf_tMglo4f_O8DPYT7PSBlBx0HPYI7VfMY7nUtKq-ewPhztQrRWg1razanbJIWeW7uGJn8mScEycrGs_lqyagBSwgpYAiFmaNPC9ZleF09hR_HR98_jeO--0LsUICt4lx4x2VdZRq_ctI7stwTYBNOkS-11No7VBitRaXJ504JTYCgRkTiUMbZ7BkMmrapXgCz3udJUXrUfiohZFHy2qe51XXhVIkYIgK-poBxfWly6pDx2wQXeaZMRzWDVDOBaiaN4P3mmrOuMMetsw-JsJuZVFQ7HGgXv0y_Ro3OrbJZJrm2tRC1VN7rPPGoZzvlc-UieItssfUb44Ovho6Ro0poxS95BHtrcpt-O1iaa1pH8GZzGhcykapsqvaC5lCaL2qP-Dqed0y2-asMYS_SQUcgt9hv6162zzTz01AsXBYaQR1e-WHNqNe39e_39fL2p3gFuymtII7Lp9iDwWpxUb2Gu-5yNV8uRrAjZzKMatQvyFGwdeB4kk5plDgOp19Opj__APOLPDo
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAioX3o9AAYPgBFHj2EnsA0KFUm3VZcWhSHtzYztpV0JJ2d0W7Z_iNzKTx1ZLRW89cMvDednfzHwTz3gA3pQqcbpQeSjzwoayFDq0qXVhig5RpHQpvW-LTWSjkRqP9bc1-N3nwlBYZa8TG0Xta0f_yLdimQmyxTH_ePIzpKpRNLval9BoYbFfLH6hyzb7sLeD4_s2jne_HHwehF1VgdChYp6HifSOZ2UhNO5y4tMi8UREpFM0R5hr7R06QtaiM-ATp6QmQ1eipXWou63A-16D66jHMwohy8bZ8p9OJARRiC43JxJqaya5pCwh9NEiFB0exiv2rykTgFbtmIIwLzLci4Gaf83WNkZw987_1n134XZHt9l2Kx_3YK2o7sPNtgDn4gEMdop5E4tWsbpkE8qVqVGiJo7RhAbzxI9ZXnk2mc8YlZdpAiYYEn3maGvK2vy1xUP4fiWf8QjWq7oqngCz3idRmnv07QopszTnpY8Tq8vUqRwZUgC8H3HjuoXXqf7HD9MEAAhlWpQYRIlpUGLiAN4trzlplx25tPUnAtKyJS0Z3hyop0em00BGJ1ZZITKubSllmSnvdRJ5RLFTPlEugNcIw5V7DLaHho7RNJzUip_xADZ7eJlO2c3MObYCeLU8jWqKhiqvivqU2lASM_rG2B2PW1AvHyWQ1OM46ACyFbivvMvqmWpy3CyFnqUaKSte-b4XjPPX-nd_Pb38K17CxuDg69AM90b7z-BWTNLLUXTTTVifT0-L53DDnc0ns-mLRvwZHF61wPwBpnmNCA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKeYgL70eggEFwgmjj2E7sA0KFstqqZbUHkHpzYzumK6Gk7G6L9q_x65jJY6ulorceuOVhO4n9zSsz4yHkdVDS6VIVsShKG4vAdWwz6-IMDKJE6SC8b4tN5OOxOjjQkw3yu8-FwbDKnic2jNrXDv-RD1KRc5TFKRuELixisjP8cPwzxgpS6Gnty2m0ENkrl7_AfJu_392BtX6TpsPPXz-N4q7CQOyASS9iKbxjeSi5hlOGujWXHpUS4RT6CwutvQOjyFowDLx0SmgUegGkrgM-bjmMe4VczYWUSF1f0snq_07COaoTXZ5OwtVgLpjAjCGw1xIgIxana7KwKRkAEu4IAzLPa7vngzb_8tw2AnF4-3-eyjvkVqeG0-2Wbu6SjbK6R663hTmX98lop1w0MWoVrQOdYg5NDZQ2dRQdHdSj3kyLytPpYk6x7EwTSEHBAKAOj2a0zWtbPiDfLuUzHpLNqq7Kx4Ra72WSFR5svlKIPCtY8Km0OmROFaA5RYT1q29ctyE71gX5YZrAAK5MixgDiDENYkwakberPsftdiQXtv6IoFq1xK3Emwv17LvpOJPR0irLec60DUKEXHmvZeJ1rpzyUrmIvAJIro0x2t43eA3dc0IrdsoistVDzXRMcG7OcBaRl6vbwL5wqYqqrE-wDSY3g80M0_GoBfjqURyUfVgHHZF8Dfpr77J-p5oeNVuk55kGVRZ6vuuJ5Oy1_j1fTy7-ihfkBtCJ2d8d7z0lN1MkZAZUnG2RzcXspHxGrrnTxXQ-e95wAkoOL5te_gCmqJXV
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection+of+immunogenic+cell+death+and+its+relevance+for+cancer+therapy&rft.jtitle=Cell+death+%26+disease&rft.au=Fucikova+Jitka&rft.au=Kepp+Oliver&rft.au=Kasikova+Lenka&rft.au=Petroni+Giulia&rft.date=2020-11-26&rft.pub=Springer+Nature+B.V&rft.eissn=2041-4889&rft.volume=11&rft.issue=11&rft_id=info:doi/10.1038%2Fs41419-020-03221-2&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-4889&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-4889&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-4889&client=summon